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ABSTRACT 
 
Thawing of fresh frozen plasma (FFP) in South Africa is not standardized and thawing at high 
temperatures may cause clotting factor activation and disseminated intravascular coagulation 
(DIC). This research project studies the in-vitro effects of thawing FFP at various 
temperatures on coagulation. Twenty units of FFP were each divided into 4 satellite bags 
which were respectively thawed at 22ºC, 37ºC, 45ºC and 60ºC and tested for Fibrinogen, D-
Dimers, PT, PTT, r value, Alpha Angle and Maximum Amplitude (MA). FFP thawed at 60ºC 
showed significant differences suggesting clotting factor inactivation. FFP thawed at 45ºC 
showed significantly elevated D-Dimers. Clotting factors thawed at 22ºC may be partially 
inactivated. High thawing temperatures may activate and then denature the factors therein. 
Twenty two degrees may partially inactivate FFP until it is warmed to body temperature. The 
clinical implications and recommendations of this study are to thaw FFP at 37ºC.  
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CHAPTER ONE 
OVERVIEW OF THE STUDY 
 
 
1.1 Introduction 
 
In this chapter an overview of the study is provided.  This includes the background to the 
study, the problem statement, the purpose, the objectives, the importance of the study, 
relevant definitions, overview of methodology, validity and reliability, ethical considerations 
and concludes with a brief outline of the study to determine whether Fresh Frozen Plasma 
(FFP) thawed at high temperatures causes activation of the clotting factors in FFP. 
 
1.2 Background to the Study 
 
The current practices as regards thawing of FFP in South Africa are not standardised.  FFP is 
delivered from the South African Blood Transfusion Services (SABTS) frozen.  Thawing of 
FFP is then at the discretion of medical staff prior to administration. 
 
The current recommendation by the SABTS is to thaw FFP at 37ºC in a water bath (1).  
However, the common practice in South African hospitals is to thaw FFP in a non sterile 
bucket of water, the temperature of which is often influenced by the urgency with which the 
FFP is required.  The average time to thawing of FFP at 37ºC is 35 to 45 minutes (2), which 
can be reduced by increasing the temperature of the waterbath. 
 
There are two potential problems with this practice.   
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The first is one of bacterial contamination.  Rhame and McCullough (3) report on 3 cases of 
pseudomonal septicaemia related to thawing of cryoprecipitate in a water bath and in view of 
this, recommend thawing blood products in protective plastic coverings.  This, however, has 
been shown to prolong the thawing process (4).  
 
The second potential problem with the practice of uncontrolled thawing of FFP is one of 
protein denaturation and / or possible activation when FFP is thawed at high temperatures to 
speed up the thawing process.  Administering denatured protein, in particular coagulation 
factors, is potentially hazardous in its own right as it might initiate a Disseminated 
Intravascular Coagulation and / or cause renal failure. 
 
Westphal et al (2), studied FFP thawed at 37ºC versus 56 ºC and showed no significant effect 
on the activity of clotting factors.  The coagulation tests used were Prothrombin Time (PT), 
Partial thromboplastin times (PTT), Fibrinogen and factors II, IX, X, V and VIII assays.  They 
do stress that the bags were removed as soon as they were deemed to be thawed in order to 
prevent protein denaturation.   A confounding variable in the study was that unit to unit 
variability was not taken into account.  
 
With concern for the interpretation of Westphal’s results, not to mention a flawed study 
design, Plotz and Ciotola (4) undertook a study where satellite bags of FFP, thawed at 37ºC 
and 45ºC, were compared.  Bags in the 45ºC were removed when ‘slushy’, i.e. before thawing 
was complete.  No significant differences were found in coagulation parameters and factor 
levels measured, between the 37ºC and 45ºC, while thawing time was significantly reduced, 
bearing in mind that the satellite bags were smaller in volume than typical bags of FFP.   
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Of interest are other techniques used to reduce the thawing time of FFP.  Initial reports on the 
use of microwave technology to thaw FFP found a decrease in coagulation factors which were 
deemed to be not clinically significant (5).  In contrast to the study by Thompson (5), Luff, 
Kessler and Bell (6) found significant reductions in factors IX, X, XI and fibrinogen with 
prolonged PT and PTT.  Total protein and albumin were similarly affected.  With a change in 
microwave oven, with temperature regulation or water environment microwave thawing, no 
significant decreases in factors or albumin was detected, although, flocculent material was 
noted in all techniques.  Whether this flocculent material was denatured proteins or debris 
from time of freezing is to be debated.  In all studies the time to thawing of FFP was 
significantly reduced (6,7,8). 
 
The potential deleterious effects of inducing clotting factor activation through the thawing 
process may be to induce a Disseminated Intravascular Coagulation (DIC) which in turn may 
precipitate a Systemic Inflammatory Response Syndrome (SIRS) (9,10).  Widespread 
activation of the clotting cascade leads to clotting factor consumption through microvascular 
thrombus formation ultimately leading to factor depletion and bleeding, commonly seen in 
patients with major trauma and patients receiving multiple blood transfusions (9,10).  Lack of 
coagulation inhibitors contributes to coagulation with microvascular thrombus formation 
ultimately leading to reduced capillary blood flow and tissue ischaemia and inflammation.  
Endothelial damage also contributes to the inflammatory process through neutrophil 
activation and the release of inflammatory cytokines e.g. Tumour Necrosis Factor – alpha 
(TNF α), Interleukin 1 and 6 (IL-1; IL-6) (11).   
 
These pro-inflammatory cytokines may further induce coagulation.  Monocytes release Tissue 
Factor which forms part of the initial steps in coagulation, activating platelets and binding and 
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activating Factor VII.  Factor Xa was found to produce a proinflammatory response in 
endothelial cells (12).  
 
In SIRS, an imbalance between pro coagulants and coagulation inhibitors exists.  Numerous 
studies have shown relative ‘exhausted’ coagulation inhibitors and fibrinolysis, hence the 
recent findings where Activated Protein C (APC) improved outcome in patients with severe 
sepsis (13).   
 
APC is anti-inflammatory (13). APC inhibits expression of Tissue Factor (TF), reduces 
neutrophil rolling, and inhibits proinflammatory cytokine production. 
 
Trials such as the Kybersept (14) trial studying Anti Thrombin (AT) in sepsis, the Optimist 
trial (15) looking at Tissue Factor Pathway Inhibitor (TFPI) and trials studying Platelet 
Activating Factor acetyl hydrolase (Pafase) (16) explore different ways in which to correct the 
imbalance in coagulation created by sepsis and SIRS.  AT also has anti-inflammatory 
properties in that it reduces Nuclear Factor (NF-κB) production.  NF-κB is a transcription 
factor involved in immediate early gene activation during inflammation (17). 
 
A further complication of a DIC is platelet consumption and thrombocytopenia. Platelet 
activation results in platelets binding not only to the endothelium and fibrin but also to 
neutrophils.  This widespread platelet activation also contributes to microvascular thrombus 
formation and reduced blood flow.  The thrombocytopenia may further contribute to the 
bleeding. 
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The potential deleterious effects of administering denatured clotting factors are difficult to 
ascertain as there are no studies where this has been directly addressed.  The assumption can 
be made that intravenously administered denatured clotting factors would be sequestrated in 
the lung and kidney, potentially reducing capillary blood flow with endothelial dysfunction.  
This in turn could produce a localized inflammatory process leading to acute lung injury and / 
or acute renal failure.  
 
1.3 Research Problem 
 
Clinical experience and anecdotal reports suggest that the SABTS standardized method of 
thawing FFP at 37ºC is not adhered to and that FFP is thawed in a basin or bucket with water 
temperatures varying depending on the urgency to administer the FFP. 
 
It has been shown that FFP thawed at high temperatures may denature clotting factors but 
does not induce clotting factor activation.  These studies however were flawed in study design 
and hence the conclusions drawn may not be accurate.   
 
The potential deleterious effects of administering activated clotting factors or denatured 
proteins, produced through the thawing process, are DIC and or SIRS in patients who by the 
very reason for requiring FFP, are already at risk for or have a DIC and SIRS. 
 
No study to date has adequately addressed the issue of clotting factor activation and 
denaturation. 
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1.4 The purpose of the study 
 
The purpose of this research project is to study the in-vitro effects of thawing FFP at various 
temperatures on coagulation parameters. 
 
1.4.1 Hypothesis 
 
There is no positive correlation between clotting factor activation and defrosting at high 
temperatures. 
 
1.4.2 Aim 
 
The aim of the study is to determine FFP activation with defrosting at different temperatures. 
 
1.4.3 Objectives 
 
To determine clotting factor activation at different temperatures (22°C, 37°C, 45°C, 60°C) by 
using the following tests: 
• Fibrinogen 
• D-Dimers 
• PT 
• PTT 
• TEG analyses of r value, Alpha angle and Maximum Amplitude 
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1.5 Research Design 
 
An experimental, quantitative, randomized, controlled study design was used to determine the 
in vitro effect of thawing FFP on clotting factor function. 
 
1.6 Research Method and Sampling 
 
1.6.1 Preparation of FFP 
 
The FFP used in this study was prepared by the SABTS according to their standard operating 
procedures (SOP).  
 
Adult units of FFP were each divided into 4 satellite bags prior to freezing and storage 
according to the SABTS SOP. Each satellite bag was assigned to one of 4 temperature groups 
viz. 22°C, 37°C, 45°C and 60°C. A total of 20 adult units of FFP were divided and stored for 
the purposes of this research project. Thawing temperatures were chosen based on similar 
temperatures used in other research on the effect of thawing temperatures on FFP. 
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1.6.2 Sampling 
  
Figure 1.1: Flow diagram of sampling process 
 
 
1.6.3 Laboratory work 
 
The routine coagulation tests were performed by an experienced haematology registrar, with 
the assistance of qualified laboratory technicians of the Haematology Laboratory of the 
Johannesburg Hospital, using the laboratories SOP. The TEG tests were performed by the 
researcher using the TEG Series 5000 SOP.  All laboratory equipment was calibrated prior to 
this research project. 
FFP was thawed in a standard waterbath. 
• Calibration of 
laboratory machinery 
used for Fibrinogen, 
D-Dimers, PT, PTT 
measurements 
• Pre heat water bath 
Thawing FFP 
satellite bags 
assigned to the 
22°C group first, 
followed by 
37°C, 45°C & 
60°C groups 
 
• Calibration of TEG 
series 5000 used for 
TEG analysis 
• Pre heat water bath 
Thawing FFP 
satellite bags 
assigned to the 
22°C group first, 
followed by 
37°C, 45°C & 
60°C groups 
• Laboratory testing 
• Data collection 
• Laboratory testing 
• Data collection 
20 
Units 
37 
°C
22 
°C
45 
°C
60 
°C
40 
Units 
40 
Units 
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1.7 Data Collection 
 
Data was collected by the investigator in hard copy and compiled on a SPSS data table. 
 
1.8 Data analysis 
 
Data was analysed using the appropriate parametric as well as non parametric tests, to 
describe differences between the variables thawed at different temperatures. 
 
1.9 Reliability 
 
Laboratory tests were performed using the standard operating procedures at the Haematology 
laboratory at the Johannesburg Hospital.  
 
TEG tests were performed on calibrated TEG 5000 machines.  Two samples from each 
satellite bag were simultaneously tested and the results thereof statistically compared with 
each other. No statistical difference was found between these 2 samples and is further 
discussed in Chapter 4. 
 
1.10 Validity 
 
The PT, PTT, Fibrinogen and D-Dimers provide a comprehensive analysis, and hence the 
effect of thawing temperature, on standard in-vitro coagulation pathways. The TEG provides 
a cost effective general overview of coagulation activity.  
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1.11 Ethics 
 
Approval to conduct the study was received from the Committee for Research on Human 
Subjects (medical), ref: R14/49 Levy. 
 
1.12 Overview of the study 
 
This study will be presented as follows: 
 
Chapter 1: Overview of the study 
This chapter provides an overview of the study and includes the background to the study, the 
problem statements and purpose of the study and a brief explanation of the research 
methodology. 
 
Chapter 2: Literature review 
In this chapter, a review of the literature relevant to the various aspects of the study is covered.  
 
Chapter 3: Research methodology 
This chapter describes the research methodology used in this study including the research 
design, the study setting, the sampling process and data collection procedures.  
 
Chapter 4: Data analysis and discussion of results 
In this chapter the results of both the classic and TEG data will be analysed. 
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Chapter 5: Summary, conclusions, limitations and recommendations. 
In this chapter a summary and conclusions from the main findings are presented, followed by a 
discussion of the limitations of the study and recommendations for clinical practice and for 
further research in this area. 
 
1.13 Summary 
 
Thawing of FFP in South Africa is done at the discretion of the attending medical staff.  
Current guidelines advise thawing FFP at 37ºC, however, this is often not the case when time is 
of the essence.  There are potential serious deleterious effects of thawing FFP at high 
temperatures e.g. DIC and SIRS.  These deleterious effects could be potentially fatal in the 
already compromised recipient.  If knowledge of the effects of thawing FFP at high 
temperatures is known, this could aid in changing current practice and thereby potentially 
improving the outcome of patients receiving FFP. 
 
 
 
 
 
 
 12
CHAPTER TWO 
REVIEW OF THE LITERATURE 
 
 
2.1 Introduction 
 
In this chapter a review of the literature is discussed.  This includes an overview of prior 
research on thawing of FFP followed by a discussion on the potential effects of administering 
activated coagulation factors. To best understand the choice of clotting factor tests in this 
study we will review the coagulation pathway followed by a brief review of the conventional 
tests and Thromboelastography used to assess clotting factor function. A comparison of TEG 
versus conventional tests for coagulation is discussed followed lastly by the preparation and 
content of FFP. 
 
2.2  Research on thawing of FFP 
 
The South African Blood Transfusion Services currently recommends that FFP be thawed at 
30 - 37°C (1). The average time to thawing of FFP at 37ºC in a water bath is 35 to 45 minutes 
(2), however FFP is often thawed at higher temperatures in order to expedite the thawing 
process.  
 
Thawing of blood products in a non-sterile water-bath can potentially cause bacterial 
contamination.  Rhame and McCullough (3) reported on 3 cases of pseudomonal septicaemia 
related to thawing of cryoprecipitate in a contaminated water bath.  In view of this they 
recommended thawing blood products in protective plastic coverings despite a prolongation 
in the thawing process (4).   
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Various methods of thawing FFP have been studied in an attempt to expedite the thawing 
process.  Westphal et al (2), studied FFP thawed at 37ºC versus 56 ºC and showed no 
significant effect on the activity of clotting factors.  The coagulation tests used were 
Prothrombin time (PT), Partial thromboplastin times (PTT), Fibrinogen and factors II, IX, X, 
V and VIII assays.  They do stress that the bags were removed as soon as they were deemed 
to be thawed in order to prevent protein denaturation.   A confounding variable in the study 
was that unit to unit variability was not taken into account.  
 
Due to concern for the interpretation of Westphal’s results, not to mention a flawed study 
design, Plotz and Ciotola (4) undertook a study where satellite bags of FFP, thawed at 37ºC 
and 45ºC, were compared.  Bags in the 45ºC were removed when ‘slushy’, i.e. before thawing 
was complete.  No significant differences were found in coagulation parameters and factor 
levels measured, between the 37ºC and 45ºC, while thawing time was significantly reduced, 
bearing in mind that the satellite bags were smaller in volume than typical bags of FFP.   
 
Microwave technology is another method which has been used to thaw FFP rapidly.  Initial 
reports found a decrease in coagulation factors deemed to be not clinically significant (5).  In 
contrast to the study by Thompson (5), Luff, Kessler and Bell (6) found significant reductions 
in factors IX, X, XI and fibrinogen with prolonged PT and PTT.  Total protein and albumin 
were similarly affected.  A further concern relating to microwave thawing was the uneven 
distribution of heat within the FFP being thawed, creating “hot spots” with the risk of clotting 
factor protein denaturation (5).  There is anecdotal evidence, via personal communication, of 
6 patients who developed DIC following a transfusion of FFP thawed in a conventional 
microwave oven. 
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A change in microwave oven technology, specifically designed for the purposes of thawing 
blood products e.g. the Transfusio-therm 2000R (Figure 2.1), has overcome these problems 
with the added benefit of reduced thawing times of FFP, no effect on clotting factors and also 
avoiding the risk of bacterial contamination (7,8,9,10).  There is still concern, however, for 
detrimental effects on Packed Red Cells warmed in these devices (11). 
 
 
 
 
 
Figure 2.1: The Transfusio-therm 2000R 
 
2.3 Potential deleterious effects of activated clotting factors 
2.3.1 Coagulation system 
• Platelets 
Thrombocytopenia is a common finding among patients with sepsis and is also used as an 
indicator of severity.  Sepsis induced endothelial activation causes platelet activation by the 
exposure of TF as well as from circulating cytokines.  This leads to platelet aggregation and 
adhesion not only to the endothelium and fibrin but also to neutrophils.  Widespread platelet 
activation contributes to microvascular thrombus formation and reduced blood flow.  The 
imbalance of the pro-coagulation versus anti-coagulation pathways together with platelet 
activation leads to thrombocytopenia (12,13). 
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• Disseminated intravascular coagulation 
Widespread activation of the clotting cascade leads to clotting factor consumption ultimately 
leading to factor depletion and bleeding commonly seen in major trauma, massive blood 
transfusion patients (14,15).  The hypothesis of administering activated clotting factors is that 
this could induce widespread activation of clotting factors leading to a consumptive 
coagulopathy or DIC.  While there is no evidenced-based data to support that activated 
clotting factors alone may precipitate a DIC, it may still be a precipitating cause of DIC (16).   
 
Should the administration of “activated” FFP precipitate a DIC, thrombocytopenia would 
once again be an associated complication.  
 
2.3.2 Immune system 
 
Endothelial damage or activation associated with sepsis, activates neutrophils with the 
resultant release of inflammatory cytokines e.g. Tumour Necrosis Factor – alpha (TNF α), 
Interleukin 1 and 6 (IL-1; IL - 6).  These inflammatory mediators initiate coagulation (17).  
Monocytes also release TF which, as illustrated above, is part of the initial steps in 
coagulation (18). 
 
The ancestral relationship of coagulation and inflammation is well illustrated in the Limulus 
Test.  It was discovered that blood in the presence of the Limulus amebocyte coagulated when 
exposed to certain factors (19).  This was also noted in the Horseshoe crab (Limulus 
polyphemus) when exposed to Gram-negative bacteria and similarities were also found in 
mammals (20).  The Limulus Test is based on the ability of test material to initiate 
coagulation of Limulus lysate.  It has been used as a sensitive test for bacterial endotoxin in 
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pharmaceutical preparations, food, water supplies as well as in blood, urine and cerebrospinal 
fluid (20).  A study of different strains of Neisseria using the Limulus test found the Lipid A 
component of endotoxin to possess the majority of the procoagulant activity (21).  Lipid A is 
also the major initiator of the inflammatory response (22).   
 
While proinflammatory cytokines may induce coagulation, there is also data suggesting that 
coagulation itself can induce inflammation through the release of inflammatory cytokines 
(23,24). Factor Xa was found to produce a proinflammatory response in endothelial cells (18) 
and Activated Protein C (APC) was also found to be anti-inflammatory (25). APC inhibits 
expression of TF, reduces neutrophil rolling, and inhibits proinflammatory cytokine 
production.  Anti-Thrombin (AT) reduces Nuclear Factor (NF-κB) production (10), NF-κB 
being a transcription factor involved in immediate early gene activation during inflammation 
(26). 
 
The relationship between coagulation and inflammation is further highlighted by the 
imbalance that exists between pro coagulants and coagulation inhibitors in patients with 
sepsis.  Numerous studies have shown a relative ‘exhausted’ coagulation inhibitors and 
fibrinolysis, hence the recent findings where APC improved outcome in patients with severe 
sepsis (25).  Lack of coagulation inhibitors allows for unimpeded coagulation with 
microvascular thrombus formation and reduced capillary blood flow, and an associated 
increase in organ failure, morbidity and mortality (16, 23).  Trials such as the Kybersept trial 
(27) looking at AT in sepsis, the Optimist trial (28) looking at TF Pathway Inhibitor (TFPI) 
and trials studying Platelet Activating Factor acetyl hydrolase (Pafase) (29) are exploring 
ways to correct the imbalance in coagulation created by sepsis. 
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The effect of administering activated clotting factors may however not be deleterious (16). 
Numerous studies have demonstrated a beneficial effect of administering activated factor VIIa 
in patients with ongoing blood loss (30,31) and activated Protein C has been shown to be of 
benefit in patients with severe sepsis as illustrated above (15, 17). Hence the effects of 
administering activated FFP may not be deleterious at all. 
 
2.4 The coagulation system 
 
The coagulation system is a complex system of interactions with the ultimate aim of 
haemostasis in the body.  As illustrated above, it is linked to the immune system and has a 
marked effect on the inflammatory response in patients. 
 
To follow is an overview of the coagulation system and the appropriate tests of the 
coagulation system. 
2.4.1 Platelets (22,32) 
 
Platelets play a key role in the first steps of the coagulation pathway.   
• Vascular injury exposes subendothelial matrix, collagen, to soluble protein, von 
Willebrand factor (vWf).  vWf attaches to the subendothelial matrix, exposing multiple 
Glycoprotein 1b (G1b) binding sites for the G1b, glycoproteins found on platelet 
membranes. 
• Platelet adhesion to the subendothelial-vWf complex occurs and results in platelet 
activation 
• Platelet activation exposes Glycoprotein IIb/IIIa (GIIb/IIIa) binding sites for further 
attachment of vWf and fibrinogen.  At the same time dense granules are released from 
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platelets.  These contain ADP which enhances platelet adhesion and activation, 
thromboxane A2 and serotonin which cause vasoconstriction, and calcium which is 
necessary for activation of proteins in the coagulation pathway.  Alpha granules in 
platelets release fibrinogen, fibronectin, factor V, factor VIII and thrombospondin.  Lastly, 
phosphatidylserine is exposed which serves as a platform for the initiation of the 
coagulation cascade. 
2.4.2 Coagulation Pathway (19) 
 
 
 Figure 2.2: The coagulation pathway (adapted from Medinfo (33)) 
 
• Exposure of TF to factor VII (fVII) in the presence of calcium initiates the coagulation 
pathway. 
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• TF – fVII complex activates factor IX (fIXa) and factor X (fXa) 
• fIXa in the presence of fVIII, further activates fX to fXa in large amounts facilitating a 
“thrombin burst” 
• fXa converts prothrombin to thrombin (fIIa), facilitated by fVa 
• Thrombin then 
o  induces fVIII and fV 
o induces fXI to fXIa which in turn activates fIX to fIXa 
o enhances platelet aggregation and activation 
o converts fibrinogen to fibrin, which polymerises to form fibrin clot. 
• fXIIIa (activated by fIIa and calcium) stabilises the clot through covalent bonds between 
the fibrin molecules. 
 
2.4.3 Inhibition of the Coagulation Pathway (19,32) 
 
• Prostaglandin I2 released from intact endothelium causes vasodilation and inhibits platelet 
activation. 
• Antithrombin, a serine protease inhibitor (serpin), and heparin sulphate from the 
endothelium, inhibit thrombin, fIXa, fXa, and fXIa. 
• Protein C, activated by the thrombin-thrombomodulin complex, inactivates fVa and fVIIIa 
in the presence of co-factor, Protein S. 
• TF Pathway Inhibitor (TFPI) binds to fXa and TF-fVIIa complex inhibiting this 
“extrinsic” component of the pathway. 
• Tissue Plasminogen activator (tPA) is released from the damaged endothelium and 
stimulates the fibrinolytic pathway. 
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 Figure 2.3: Inhibition of the coagulation pathway (adapted from Medinfo (33)) 
 
2.4.4 Fibrinolytic pathway (22,32) 
 
• tPA and Urokinase are released from damaged endothelium and in response to thrombin.  
Plasmin is cleaved from plasminogen bound to fibrin within the clot. 
• Plasmin degrades fibrin to D-Dimers and fibrin degradation products (FDPs) 
• Plasmin also degrades fVa, fVIIIa and GPIb 
• fXII is activated by the negatively charged subendothelium, which cleaves kallikrein from 
prekallikrein in the presence of kininogen. 
• Kallikrein further cleaves plasmin from plasminogen and releases bradykinin from 
kininogen, the link to the pro-inflammatory process. 
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2.4.5 Regulation of Fibrinolysis (19,22,32) 
 
• Plasminogen Activator Inhibitor I (PAI 1) is released from activated platelets, and inhibits 
tPA and Urokinase as well as inhibiting the activation of  prekallikrein to kallikrein.  
Protein C inhibits PAI 1 
• Alpha 2 antiplasmin and alpha 2 macroglobulin prevent the formation of plasmin from 
plasminogen and also inactivate free plasmin, creating a plasmin-alpha 2 antiplasmin 
(PAP) complex. 
 
2.5 Conventional tests of the coagulation system (32) 
 
2.5.1 Fibrinogen 
 
As mentioned above, fibrinogen is cleaved to fibrin through the action of Thrombin.   
 
Hypothesis of the test: A low fibrinogen level would suggest an activated coagulation cascade 
with the formation of increased amounts of thrombin and hence large amounts of fibrinogen 
being cleaved to fibrin. 
 
2.5.2 D-Dimers 
 
D-Dimers are breakdown products of fibrin.  Elevated D-Dimers are found in situations where 
fibrinolysis is taking place. 
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Hypothesis of the test: D-Dimers should be elevated if FFP is activated leading to thrombus 
formation and subsequent fibrinolysis.  
 
2.5.3 Prothrombin Time 
 
To test the PT a 3.8% trisodium citrate anticoagulant is added to the specimen of plasma or in 
this case FFP, in a 9:1 ratio.  This is then centrifuged to produce platelet poor plasma (PPP).  
Calcium + thromboplastin are then added and time to fibrin strand formation is measured, 
either by optical or electromechanical device.  The PT tests the “Extrinsic Pathway”. 
 
Hypothesis of the test: Activated clotting factors would produce a shorter time to fibrin strand 
formation and hence a shorter PT. A prolonged PT would suggest factor deficiency or the 
equivalent e.g. denaturation. 
 
2.5.4 Partial Thromboplastin Time  
 
A specimen, in this case FFP, is “activated” by negatively charged Kaolin or Celite. Partial 
thromboplastin, also called cephalin, is a phospholipid component which is then added to this 
“activated” specimen. Time to fibrin formation is measured.   
 
Hypothesis of the test: As with the PT, a short PTT would suggest factor activity. A 
prolonged PTT would suggest factor deficiency or the equivalent e.g. denaturation. 
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Large amounts of activated FFP could potentially also increase the PT and PTT due to factor 
depletion following activation. 
 
2.6 Thromboelastography 
 
A sample of celite or kaolin activated whole blood (0.4ml) is placed into a pre warmed 
cuvette to 36 C. A pin suspended from a torsion wire is then lowered into the cuvette. The 
cuvette is rotated backward and forwards in a small arc. As the fibrin strands interact with the 
activated platelets on the surface of the pin, the rotational movement of the cuvette is 
transmitted to the pin. The stronger the clot the more the pin moves. The Haemoscope is 
connected to a computer and the coagulation profile is then displayed on the screen as an 
outline of a thromboelastogram (31, 32, 34). Various parameters are evaluated. There are no 
normal values for FFP measured with TEG.  
 
Figure 2.4: The thromboelastogram (32) 
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2.6.1 r value 
 
This is the time taken from initiation of the test to the initial fibrin formation and pin 
movement.  This value is indicative of factor activation. 
 
Hypothesis of the test: A short R value would suggest factor activation as would be seen in 
‘Hypercoagulation’ in Figure 2.5 and a prolonged R value would suggest factor deficiency.  
 
2.6.2 Alpha Angle and K Value 
 
The Alpha Angle is the angle between the line in the middle of the TEG tracing and the line 
tangential to the developing "body" of the TEG. The K value is the measure of time from the 
beginning of clot formation until the amplitude of the TEG reaches 20mm. Both the alpha 
angle and K value are indicative of factor activation and amplification. Only the Alpha Angle 
will be analysed in this study. 
 
Hypothesis of the test: A widened Alpha Angle would imply clotting factor activation as 
would be seen in ‘Hypercoagulation’ in Figure 2.5 and a narrow angle would suggest factor 
deficiency. 
 
2.6.3 Maximal Amplitude 
 
The Maximum Amplitude (MA) is the greatest amplitude of the TEG tracing. It is a measure 
of platelet aggregation. 
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Hypothesis of the test: The MA is suspected to be larger if the clotting factors are activated 
even though FFP is platelet poor as would be seen in ‘Hypercoagulation’ in Figure 2.5.  A 
narrow MA would imply clotting factor deficiency. 
 
2.6.4 MA 60 
 
The MA 60 is the amplitude of the TEG tracing at 60 minutes and is a measure of clot lysis. 
This value is mentioned for completeness and was not included in the research project 
because it does not contribute to the objective of determining clotting factor activation.  
 
 
Figure 2.5: Overview of TEG interpretation (35) 
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2.7 Comparison of TEG versus conventional tests of coagulation 
 
The traditional explanation of the coagulation pathway into intrinsic and extrinsic pathways 
has been superseded by a theory of enzyme complexes interacting with cells and coagulation 
factors until fibrin is formed.  
 
Coagulation, or fibrinolysis, within flowing blood is obviously different to what one would 
find in the lab, using either conventional tests of coagulation or TEG. As discussed above, 
coagulation involves platelet interaction with clotting factors and a balance between 
fibrinolysis and fibrin formation. In the measurement of haemostasis it is argued that TEG 
provides a more global picture because it measures the net product of both the coagulation 
and fibrinolytic systems in that it is a whole blood investigation as apposed to conventional 
tests of a) coagulation namely PT and PTT, b) fibrinolysis namely D-Dimers and FDPs, and c) 
platelets, number or function (i.e. bleeding time) (34).  As an example, a hypercoagulable state, 
as in the case of DIC, will show elevated D-Dimers and FDPs but may only show an elevated 
PT or PTT once the clotting factors become depleted, while the TEG may show an initial 
hypercoagulable state with increased clot lysis followed by delayed minimal coagulation (see 
Overview of TEG interpretation) 
 
The TEG therefore provides for a continuous assessment of the developing clot, clot strength 
and stability as well as clot lysis. 
Furthermore, in studies comparing TEG and conventional tests, Essell et al (36) found TEG 
(71%) to have similar sensitivities to bleeding time (71%) and platelet count (100%) but 
better specificity, 89% versus 78% and 53% respectively. Similar findings were reported 
comparing TEG to PT and APTT.  
 27
 
 
Figure 2.6: Extrinsic and Intrinsic Coagulation Pathways (19)  
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TEG has also been found to be a useful monitor in guiding transfusion algorithms as well as 
predicting which patients may bleed, particularly in cardiac and liver transplant surgery (37). 
 
The traditional approach to the coagulation system of Extrinsic and Intrinsic pathways is still 
useful, however, for in vitro analysis and the understanding of the coagulation pathways.  The 
PT and PTT are particularly useful for monitoring the effects of anticoagulants warfarin and 
heparin respectively or the ill effects of liver dysfunction and or vitamin K deficiency 
resulting in a prolonged PT. 
 
2.8 Fresh Frozen Plasma 
 
2.8.1 Preparation of FFP 
 
Within 18 hours of donation, fresh frozen plasma (FFP) is separated from whole blood and 
frozen to below -18ºC.  It contains all the clotting factors at normal physiological levels and is 
+/- 280 ml in volume. 
 
The current recommendation by the South African Blood Transfusion Services is to thaw FFP 
at 30ºC - 37ºC and it should be transfused as rapidly as possible, 15 – 20 min per unit (1).  
The reason for this is the lability of the coagulation factors which deteriorate within a few 
hours. 
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2.8.2 Content of FFP 
 
The content of FFP is given in Table 2.1 and Table 2.2 below. 
 
Table 2.1: Average levels of coagulation factors in a unit of FFP (1) 
Factor Average levels per unit of FFP 
Fibrinogen 200mg 
Factor II 1.03 μ/ml 
Factor V 0.64 μ/ml 
Factor VII 1.21 μ/ml 
Factor VIII 0.85 μ/ml  
Factor IX 0.91 μ/ml 
Factor X 1.25 μ/ml 
Factor XI 0.79 μ/ml 
Antithrombin 104% 
Plasma pseudocholinesterase 3000 – 10000 iu/l 
 
 
Table 2.2: Average levels of solutes in FFP (1) 
Solute Average levels per unit of FFP 
Glucose 24.8 mmol/l 
Potassium 3.0 mmol/l 
Sodium 165 mmol/l 
Chloride 79 mmol/l 
Osmolarity 322 mmol/l 
pH 7.9 
 
 
2.9 Summary 
 
The coagulation system is a complex interaction of enzymes, cells, clotting factors balancing 
coagulation and fibrinolysis. There are both conventional tests and TEG which can be used to 
assess the coagulation system with some evidence to suggest that TEG possibly gives a more 
global picture of the coagulation system. 
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FFP is collected, prepared and stored under stringent protocol by the SABTS. Consensus is 
that FFP should be thawed at 30°C and used shortly thereafter. Little evidence exists to 
corroborate detrimental effects of thawing FFP at higher temperatures. 
 
The hypothesized effects of administering activated FFP includes thrombocytopenia, DIC and 
possibly induction of an inflammatory response.  This effect was not looked at in this study as 
this study was confined to in vitro testing only. 
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CHAPTER THREE 
RESEARCH METHODOLOGY 
 
3.1 Introduction 
 
A detailed explanation of the research methodology is discussed under the headings of FFP 
preparation, thawing of FFP, laboratory measurements and TEG studies. Standard operating 
procedures for the SABTS, Haematology laboratory at the Johannesburg Hospital and TEG 
5000 series are provided as appendices. 
 
3.2 Hypothesis 
 
There is no positive correlation between clotting factor activation and defrosting at high 
temperatures. 
 
3.3 Aim 
 
The aim of the study is to determine FFP activation with defrosting at different temperatures. 
 
3.4 Objectives 
 
To determine clotting factor activation at different temperatures (22°C, 37°C, 45°C, 60°C) by 
using the following tests: 
• Fibrinogen 
• D-Dimers 
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• PT 
• PTT 
• TEG analysis of r value, Alpha Angle and Maximum Amplitude 
 
3.5 Research design 
 
An experimental, quantitative, randomized, controlled study design was used to determine the 
in vitro effect of thawing FFP on clotting factor function. 
  
3.6 Research method 
 
3.6.1 Preparation of FFP 
 
The Fresh frozen plasma used in this study was prepared by the South African Blood 
Transfusion Services (SABTS) according to their standard operating procedures.  
 
Donated blood units were centrifuged using either a Hettich or Sorval blood bag centrifuge 
and plasma was separated from the whole blood using the Optipress system. A quad pack of 
PL1240 bags were connected to the plasma unit using a Terumo Sterile Connecting Device. 
The contents of the plasma unit (220-290ml) were equally separated into the attached four 
bags. The aliquoted units were labeled and detached from each other using a heat sealer and 
the units were frozen using the blast freezing method. The units were stored below –25ºC.  An 
initial ten adult units of FFP were divided into four satellite units as described above on which 
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Fibrinogen, D-Dimers, PT and PTT tests were performed.  A further ten units were also 
divided into four satellite units on which TEG tests were performed. 
 
3.6.2 Sampling 
 
3.6.2.1 Calibration of laboratory machinery 
 
The laboratory machinery that was to be used to measure Fibrinogen, D-Dimers, PT, INR and 
PTT, was calibrated by an experienced haematology registrar using the standard operating 
procedure of the Haematology Laboratory in the Johannesburg Hospital. 
 
TEG 5000 series machines were used for TEG analyses of thawed FFP. These were calibrated 
by a representative of the manufacturer using the standard operating procedure for TEG 
calibration. 
 
3.6.2.2 Thawing of FFP 
 
Each of the satellite units of FFP was thawed in a  standard  water bath at 22ºC, 37ºC, 45ºC 
and 60ºC respectively. Thawing times were recorded but are not reported as they are expected 
to vary depending on the volume of each bag. There was no manual agitation of the bags 
except the minimum required to determine whether the contents were fully thawed. Bags were 
removed as soon as they were judged fully thawed. The laboratory test were initiated on bags 
that were thawed in 22°C followed by thawed FFP at 37°C, 45°C and then 60°C. 
 
 34
All satellite bags within each temperature group were defrosted at the same time in the 
“conventional” coagulation test arm, and tested simultaneously. Only those satellite bags 
within each temperature group which were to be tested immediately with TEG were thawed 
as each TEG could take between 30 and 60 minutes and only 4 TEG runs could be performed 
at one time. This was done in order to avoid a break in the cold chain or delayed testing once 
defrosted.  Three satellite bags in the 22°C group which were however stored in a 
conventional freezer overnight, were found partially thawed.  The results from these bags 
were not included in the statistical analysis. 
  
3.6.2.3 Measurement of PT, PTT and D-Dimers and Fibrinogen 
 
PT, PTT, D-Dimers and fibrinogen levels were measured according to the standard operating 
procedures of the Johannesburg Hospital Haematology Laboratory. PT, PTT and D-Dimers 
were tested according to standard laboratory operating procedures using the ACL Futura (Ilex 
Medical Systems). Fibrinogen assays were run on the ACL 7000 (Ilex Medical Systems). If 
the fibrinogen level of a particular sample was not detectable, that sample was diluted 1 in 2 
with standard plasma of known fibrinogen level. If the fibrinogen level of the diluted sample 
was less than or equal to half of the fibrinogen level in the undiluted standard plasma, the 
fibrinogen level of the original sample was taken to be zero. This was recorded as 0.1g/l for 
statistical purposes. 
 
3.6.2.4 Thrombo-Elastogram Studies 
 
Four TEG series 5000 machines were used. One machine belonged to the Anaesthetic 
Department of the Johannesburg Hospital and the other machines were on loan from Manta-
 35
Draeger.  Each machine was calibrated and balanced according to manufactures specifications 
prior to running samples.   
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: TEG series 5000 machine 
 
‘Cups and pins’ were supplied by Manta-Draeger as were the Kaolin sample bottles.  ‘Cups 
and pins’ and Kaolin sample bottles were all within their expiry date. TEG ‘pins & cups’ were 
placed in the TEG machine, according to the manufacturer’s guidelines, prior to testing.  
20uml of CaCl2 was added to each cup in every test.  Two samples from each unit of thawed 
FFP were tested.  The samples were first placed in kaolin specimen bottles and shaken.  A 
volume of 340uml of thawed FFP were sampled from kaolin specimen bottles within two 
minutes of FFP being added to the kaolin bottles, and added to the TEG cup and the TEG test 
started.  R values, Alpha angles, Mean Amplitude (MA) were recorded.  The CaCl2 and 
340uml of FFP were measured using a Pipette, set at these volumes. 
 
 36
3.6.3 Data collection and management 
 
All standard coagulation tests was performed on one day with the help of an experienced 
haematology registrar (Dr M Isaacs) and experienced laboratory personnel of the 
Haematology Laboratory of the Johannesburg Hospital. 
 
TEG testing was performed by the investigator with help from Dr Isaacs over a 2 day period. 
 
Data was collected by the investigator in hard copy and compiled on a SPSS data table. 
 
3.6.4 Data evaluation / analysis 
 
Data was analysed using SPSS version 13 and Statistix 8. The sets of data for each test 
grouped for temperature were compared and analysed. The data was tested for normality 
using the Kolmogorov-Smirnoff test. Data that was found to be parametric was tested using 
the Two-Way ANOVA for differences in coagulation tests between each temperature group. 
Data that was found to be non-parametric was analysed by transforming the data using Van 
der Waerden’s transformation and testing it using the Two-way ANOVA test. Post hoc 
analysis was performed using the Least Squares Differences. Due to the fact that there are no 
normal values for FFP using conventional or TEG studies, comparisons were tested between 
each temperature group and not against a control. Statistical analysis was done in consultation 
with statistician Professor P.J Becker, Medical Research Council, +27 12 339 8519/23.  
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3.6.5 Reliability 
 
Laboratory tests were performed using the standard operating procedures at the haematology 
laboratory at the Johannesburg Hospital. TEG tests were performed on calibrated TEG 5000 
machines.  In order to prove the reliability of the TEG testing, 2 samples from each satellite 
bag were tested simultaneously.  The results were tested using the paired Students t-Test and 
Wilcoxon Rank test. No statistically significant differences were found for either the r value 
(p = 0.125), Alpha Angle (p = 0.932) or Maximum Amplitude (p = 0.144).  Further detail is 
provided in section 4.6. 
 
3.6.6 Validity 
 
The tests chosen to prove the hypothesis were done so in consultation with a haematologist. 
The results of these tests represent a comprehensive view of the effects of thawing 
temperature on the different components of the in vitro coagulation system. 
 
3.6.7 Ethical considerations 
 
Approval to conduct the study was received from the Committee for Research on Human 
Subjects (medical), ref: R14/49 Levy. 
 
3.7 Summary 
 
The study design and laboratory tests selected allow for a reliable assessment of the effects of 
thawing temperature on FFP clotting factors in order to prove or disprove the hypothesis of 
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clotting factor activation with increasing thawing temperature. The study design allowed for 
each unit of FFP to serve as its own control. The laboratory work was performed in keeping 
with SOPs and results analysed in consultation with a statistician.  
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CHAPTER FOUR 
RESULTS AND STATISTICAL ANALYSIS 
 
4.1 Introduction 
This chapter contains the results of the laboratory work followed by the statistical analyses. 
The statistical analyses pertain to the assessment of clotting factor function at different 
thawing temperatures. 
  
4.2 Laboratory results 
The results of laboratory work are tabulated below. 
 
Table 4.1: Fibrinogen data 
FIBRINOGEN (g/l) 
Bags 22ºC       Bag no. 37ºC       Bag no. 45ºC       Bag no. 60ºC       Bag no. 
1 3.07 1 3.21  11 3.21 21 0 31 
2 3.72 2 3.99 12 3.85 22 1.91 32 
3 4.47 3 4.65 13 4.53 23 2.99 33 
4 5.52 4 6.04 14 5.71 24 2.9 34 
5 3.72 5 3.94 15 3.81 25 1.33 35 
6 2.92 6 3.24 16 3.07 26 0 36 
7 5.09 7 5.43 17 5.25 27 3.39 37 
8 5.09 8 5.52 18 5.34 28 0 38
9 4.86 9 5.01 19 5.01 29 2.34 39 
10 2.94 10 3.1 20 2.97 30 2.36 40 
E = Lab machine error report 
 
 
Table 4.2: D-Dimer data 
D-DIMERS (0.1 = 100ng/ml) 
Bags 22ºC       Bag no. 37ºC       Bag no. 45ºC       Bag no. 60ºC       Bag no. 
1 0.124 1 0.12 11 0.142 21 .092 31 
2 0.197 2 0.138 12 0.154 22 .136 32 
3 0.113 3 0.09 13 0.138 23 .156 33 
4 0.161 4 0.162 14 0.159 24 .137 34 
5 0.14 5 0.097 15 0.34 25 .093 35 
6 0.068 6 0.024 16 1 26 .109 36 
7 0.21 7 0.203 17 1 27 .204 37 
8 0.189 8 0.205 18 1 28 .313 38 
9 0.241 9 0.242 19 1 29 .296 39 
10 0.126 10 0.551 20 1 30 .594 40 
E = Lab machine error report 
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Table 4.3: PT data 
PT (sec) 
Bags 22ºC       Bag no. 37ºC       Bag no. 45ºC       Bag no. 60ºC       Bag no. 
1 13.68 1 E 11 13.7 21 120 31 
2 14.84 2 14.55 12 12.9 22 18.86 32 
3 15.71 3 15.74 13 13.8 23 16.93 33 
4 14.27 4 13.18 14 13.01 24 19.08 34 
5 15.87 5 14.78 15 14.01 25 19.21 35
6 16.5 6 15.98 16 14.54 26 27.19 36 
7 15.6 7 13.08 17 13.48 27 16.03 37 
8 18.13 8 15.04 18 15.6 28 38.41 38 
9 15.33 9 14.97 19 14.9 29 16.66 39 
10 15.58 10 15.14 20 13.8 30 14.97 40 
E = Lab machine error report 
 
 
 
 
Table 4.4: PTT data 
PTT (sec) 
Bags 22ºC       Bag no. 37ºC       Bag no. 45ºC       Bag no. 60ºC       Bag no. 
1 28.9 1 29.4 11 30.4 21 120 31 
2 27.7 2 29.1 12 28.7 22 32 32 
3 39.6 3 41.8 13 41.5 23 48.4 33 
4 22.7 4 23.3 14 23.5 24 27.3 34 
5 33.4 5 34.4 15 34.9 25 43.1 35 
6 25.1 6 25.6 16 27.1 26 44.2 36 
7 33.5 7 34.2 17 34.8 27 38.3 37 
8 31.9 8 32.7 18 34 28 66 38 
9 36.3 9 38 19 38 29 41.9 39 
10 37.4 10 39.4 20 39.4 30 42.6 40 
E = Lab machine error report 
 
 
 
Table 4.5: r-value data 
r – VALUE (min) 
Bags / Bag no. 22ºC (Ch 1 & 2) 37ºC (Ch 1 & 2) 45ºC (Ch 1 & 2) 60ºC (Ch 1 & 2) 
1   /  (1,11,21,31) 7 17.3 14.8 28.3 E 7.3 7.8 8 
2   /  (2,12,22,32) E E 7.6 7.4 6.8 7.2 28.2 28.2 
3   /  (3,13,23,33) E E 3.9 3.9 4.2 4.2 9.1 30 
4   /  (4,14,24,34) E E 11.2 13.1 7.9 11.6 8.9 8.1 
5   /  (5,15,25,35) 16.8 26.4 9.8 5.2 7 8.8 6 6.6 
6   /  (6,16,26,36) 4.8 4.1 4.6 4.8 4.3 9.3 5.3 4.1 
7   /  (7,17,27,37) 60.8 6.6 7.5 4.8 5 8.9 6.2 8.9 
8   /  (8,18,28,38) 9.3 9.9 9.2 9.1 8.9 16.4 13.9 3.5 
9   /  (9,19,29,39) E 10.1 5.1 5.2 7.8 7 30 28.6 
10 /(10,20,30,40) 10.1 E 6.9 7.9 7.2 E 0.2 7.7 
Ch = TEG channel 
E = TEG Error 
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Table 4.6: Alpha Angle data 
ALPHA – ANGLE (deg) 
Bags 22ºC (Ch 1 & 2) 37ºC (Ch 1 & 2) 45ºC (Ch 1 & 2) 60ºC (Ch 1 & 2) 
1   /  (1,11,21,31) 16.7 32.3 24.5 12.3 E 32.6 10.3 8.2 
2   /  (2,12,22,32) E E 36.4 62.9 54.3 38 0 0 
3   /  (3,13,23,33) E E 72.3 58 61.5 65.8 4.8 0 
4   /  (4,14,24,34) E E 60.3 36.3 49.5 58.1 27.7 31 
5   /  (5,15,25,35) 33.8 25.1 63.7 75.4 59.6 59.7 24.8 20.1 
6   /  (6,16,26,36) 38.4 45.5 75.3 74.7 67.6 42.7 38.1 50.9 
7   /  (7,17,27,37) 0 32.4 60.8 53.4 54.4 60 46.5 58.3 
8   /  (8,18,28,38) 53.2 52.4 41.7 51.3 52.5 38.7 32.4 40.7 
9   /  (9,19,29,39) E 59.8 54 48.5 47.8 47.7 0 1.1 
10 /(10,20,30,40) 44.4 E 42.4 57.5 36.9 E 77.5 50.5 
Ch = TEG channel 
E = TEG Error 
 
 
Table 4.7: MA data 
MA (mm) 
Bags 22ºC (Ch 1 & 2) 37ºC (Ch 1 & 2) 45ºC (Ch 1 & 2) 60ºC (Ch 1 & 2) 
1   /  (1,11,21,31) 7.7 17.1 15.9 15.9 E 18.3 6.6 4.3 
2   /  (2,12,22,32) E E 21.6 21.5 22.2 21.5 0 0 
3   /  (3,13,23,33) E E 19.4 19.3 19.1 18 2.9 0 
4   /  (4,14,24,34) E E 25.3 24.9 23.7 25.3 16.1 13 
5   /  (5,15,25,35) 21 23.4 27.2 26.2 26.6 26.6 15.9 12.5 
6   /  (6,16,26,36) 25.2 28.3 24 24.9 24.2 23.5 21.1 21.2 
7   /  (7,17,27,37) 0 26.2 26.4 52.4 17.9 25.3 23 22.8 
8   /  (8,18,28,38) 22.9 22.2 20.5 22.7 22.3 22.3 21.2 21.1 
9   /  (9,19,29,39) E 17.7 16.7 17.5 24.1 18.7 0 2.9 
10 /(10,20,30,40) 27.9 E 24.1 23.3 20.7 E 15 18.9 
Ch = TEG channel 
E = TEG Error 
 
4.3 Statistical analysis Fibrinogen, D-Dimers, PTT and PT 
 
4.3.1 Descriptive statistics of the variables grouped for temperature  
 
4.3.1.1 Fibrinogen 
 
The means, confidence intervals and standard deviations of the fibrinogen results at the 4 
different temperatures are listed in Table 4.8, followed by the Box and Whisker plot (Figure 
4.1) of these values.  There were no missing values. 
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The mean fibrinogen level is approximately 4 except in the 60ºC group where it is 1.7220. 
 
4.3.1.2 D-Dimers 
 
The means, confidence intervals and standard deviations of the D-Dimer results at the 4 
different temperatures are listed in Table 4.9, followed by the Box and Whisker plot (Figure 
4.2) of these values.  There were no missing values. 
 
The 45ºC group has a much wider inter-quartile range and a higher mean. 
 
4.3.1.3 PTT 
 
The means, confidence intervals and standard deviations of the PTT results at the 4 different 
temperatures are listed in Table 4.10, followed by the Box and Whisker plot (Figure 4.3) of 
these values.  There were no missing values. 
 
PTT levels in the 60ºC group were higher than in the other groups. 
 
4.3.1.4 PT 
 
The means, confidence intervals and standard deviations of the PT results at the 4 different 
temperatures are listed in Table 4.11, followed by the Box and Whisker plot (Figure 4.4) of 
these values.  There was 1 missing value in the 37ºC group. 
 
The PT in the 60ºC group is elevated compared to the other 3 groups. 
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Table 4.8: Descriptive statistics of Fibrinogen 
 
Descriptives
4.1400 .31203
3.4341
4.8459
4.0950
.974
.98673
2.92
5.52
4.4130 .33779
3.6489
5.1771
4.3956
4.3200
1.141
1.06819
3.10
6.04
4.2750 .32379
3.5425
5.0075
4.2678
4.1900
1.048
1.02391
2.97
5.71
1.7220 .41702
.7786
2.6654
1.7250
2.1250
1.739
1.31874
.00
3.39
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Temperature (deg C)
22
37
45
60
Fibrinogen
Statistic Std. Error
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Table 4.9: Descriptive statistics of D-Dimers 
 
Descriptives
.1569 .01657
.1194
.1944
.1572
.1505
.003
.05239
.07
.24
.1832 .04565
.0799
.2865
.1716
.1500
.021
.14436
.02
.55
.5933 .13678
.2839
.9027
.5960
.6700
.187
.43253
.14
1.00
.2130 .04910
.1019
.3241
.1986
.1465
.024
.15526
.09
.59
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Temperature (deg C)
22
37
45
60
D-Dimers
Statistic Std. Error
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Table 4.10: Descriptive statistics of PTT 
 
Descriptives
31.6500 1.73399
27.7274
35.5726
31.7056
32.6500
30.067
5.48336
22.70
39.60
32.7900 1.89581
28.5014
37.0786
32.8167
33.4500
35.941
5.99508
23.30
41.80
33.2300 1.81304
29.1286
37.3314
33.3111
34.4000
32.871
5.73334
23.50
41.50
50.3800 8.38975
31.4011
69.3589
47.7944
42.8500
703.880
26.53073
27.30
120.00
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Temperature (deg C)
22
37
45
60
PTT
Statistic Std. Error
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Table 4.11: Descriptive statistics of PT 
 
Descriptives
15.5510 .38555
14.6788
16.4232
15.5117
15.5900
1.486
1.21920
13.68
18.13
14.7178 .33464
13.9461
15.4895
14.7386
14.9700
1.008
1.00393
13.08
15.98
13.9740 .26427
13.3762
14.5718
13.9433
13.8000
.698
.83569
12.90
15.60
30.7340 10.16686
7.7350
53.7330
26.6506
18.9700
1033.650
32.15043
14.97
120.00
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Temperature (deg C)
22
37
45
60
PT
Statistic Std. Error
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Figure 4.1: Box and Whisker plot of Fibrinogen 
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Figure 4.2: Box and Whisker plot of D-Dimers 
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Figure 4.3: Box and Whisker plot of PTT 
 48
 
 
60453722
Temperature (deg C)
120.00
100.00
80.00
60.00
40.00
20.00
0.00
PT
14
8
31
 
Figure 4.4: Box and Whisker plot of PT 
 
 
It must be noted that ‘Bag number 31’ (which is the Satellite bag from Bag 1 assigned to the 
60°C temperature group) comes up as an outlier in the PTT and PT analyses and also has the 
lowest Fibrinogen and D-Dimer levels when compared to the other bags.  The reasons for this 
may be a discrepancy in the cold chain, collection process, or may simply be a cause of 
thawing at 60°C.  It is unlikely that there was an intrinsic abnormality of the FFP itself as the 
sister satellite bags did not produce outliers in the other 3 temperature groups.   
 
In order to ascertain whether any significant results would be a true difference or as a result of the 
outlier, statistics for Fibrinogen, D-Dimer, PTT and PT excluding Bag 31, were also conducted.  
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Table 4.12: Comparison of means and standard deviations in 60°C, bag 31 included and 
excluded 
 Bag 31 Included Bag 31 Excluded 
 Mean Std 
Deviation 
Mean Std 
Deviation 
Fibrinogen(g/l) 1.7220 1.3187 1.9133 1.2429 
D-Dimers 
(100ng/ml) 
.2130 .1553 .2264 .1584 
PT (sec) 30.7340 32.1504 20.8156 7.4921 
PTT (sec) 50.3800 26.5307 42.6444 10.8940 
 
 
4.3.1.5 Fibrinogen excluding bag 31 
 
The mean of the fibrinogen results with Bag 31 excluded (1.7220) is lower than the mean 
(1.9133) where bag 31 is not excluded.  
 
4.3.1.6 D-Dimers excluding bag 31 
 
The mean D-Dimer result with Bag 31 excluded is 0.2130. 
  
4.3.1.7 PTT excluding bag 31 
 
The mean PTT with Bag 31 excluded is 52.38s compared with 42.64s with Bag 31 not 
excluded. 
 
4.3.1.8 PT excluding bag 31 
 
The mean PT with Bag 31 excluded is 30.73s versus 20.81s, Bag 31 not excluded. 
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The fibrinogen and D-Dimers means were higher in the Bag 31 excluded calculations. Both 
the mean PT and PTT were lower in the Bag 31 excluded compared with Bag 31 included 
calculations. These differences were not tested for statistical significance, but rather an 
analysis of the differences between temperature groups (22°C, 37°C, 45°C, and 60°C) for 
both Bag 31 included and Bag 31 excluded was performed and follows. 
 
4.3.2 Test for normality of data in each variable, including and excluding Bag 31 
 
Each variable was tested for normality using the Kolmogorov-Smirnov Test (K-S).  The 
following was found. P-P plots and K-S tables are shown in Appendix A. 
 
The K-S statistic is significant for D-Dimers (P = 0.001), PTT (P = 0.014) and PT (P<0.000) 
in the Bag 31 included tests, implying that these variables do not follow a normal distribution.  
This is seen in the P-P Plots which show a non linear distribution of results. Fibrinogen 
however, follows a normal distribution.  The K-S test where Bag 31 is excluded also shows 
D-Dimers (P = 0.001) and PT (P = 0.006) to be significant and hence does not follow a 
normal distribution, however PTT is now shown to follow a normal distribution (P=.917).   
 
4.3.3 Statistical testing for differences in each variable grouped for temperature (Bag 
31 included) 
 
Based on the K-S test results, only the Fibrinogen variable could be tested using parametric 
tests.  Fibrinogen was tested using a Two-way ANOVA, grouped for temperature and bag 
number, followed by a paired post hoc analysis using the Least Squares Difference (LSD). 
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The D-Dimers, PTT and PT variables were tested using the Van der Waerden’s 
transformation of the data and tested with a Two-way ANOVA, grouped for temperature and 
bag number, followed by a paired post hoc analysis using the Least Squares Difference (LSD). 
  
Tables of the statistics which follow can be viewed in Appendix A. 
 
4.3.3.1 Fibrinogen 
 
The F = 42.32 of Fibrinogen has a significance of P < 0.000 which implies a statistically 
significant difference in Fibrinogen results between the 4 temperature groups.  Post Hoc 
analyses (equal variances assumed and equal variances not assumed) show statistically 
significant differences between the 60°C group and the other 3 groups (P < 0.05). The 60°C 
fibrinogen levels were significantly lower than the other in the other 3 groups. There was no 
significant difference between the 22°C, 37°C and 45°C groups.  
 
4.3.3.2 D-Dimers 
 
The Van der Waerden's transformation of D-Dimers tested with a Two-way ANOVA and post 
hoc analysis shows a significant difference (P < 0.003) between temperature groups with the 
significance coming from the difference between the 45°C group and the 22°C, 37°C and 
60°C groups (P < 0.05), the 45°C D-Dimers being significantly higher. There were no 
significant differences between the 22°C, 37°C and 60°C groups themselves.  
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4.3.3.3 PTT 
 
The Van der Waerden's transformation of PTT tested with a Two-way ANOVA and post hoc 
analysis shows a significant difference (P < 0.000) between temperature groups with the 
significance coming from longer PTT in the 60°C group compared with the 22°C, 37°C and 
45°C groups (P < 0.05). 
 
There were no significant differences between the 22°C, 37°C and 45°C groups.   
 
4.3.3.4 PT 
 
The Van der Waerden's transformation of PT tested with a Two-way ANOVA and post hoc 
analysis shows a significant difference (P < 0.000) between temperature groups.  The PT in 
the 45°C group was significantly lower than in the 22°C, 37°C and 60°C groups (P < 0.05) 
while the PT in the 60°C was significantly longer than in the other 3 groups (P < 0.05). 
 
4.3.4 Statistical testing for differences in each variable grouped for temperature (Bag 
31 excluded) 
 
To follow is the analysis of Fibrinogen, D-Dimers, PTT and PT where the outlier, Bag 31, is 
excluded from the analyses.  This will tell us whether statistics generated above are in part 
due to the outlier as apposed to the thawing process. 
 
Tables of statistics can be found in Appendix A. 
 
 53
4.3.4.1 Fibrinogen and PTT 
 
Because Fibrinogen and PTT were found to follow a normal distribution, a Two-way 
ANOVA, grouped for temperature and bag number, followed by a paired post hoc analysis 
using the Least Squares Difference (LSD) was performed.  
As in the case where ‘Bag 31’ was included, a statistically significant difference between 
groups is seen in both the Fibrinogen (P = 0.000) and PTT (P = 0.002) variables.  This 
difference stems from a statistically significant difference between the 60°C and the 22°C, 
37°C and 45°C groups in both the Fibrinogen and PTT variables (P < 0.05).  There was no 
significant difference between the 22°C, 37°C and 45°C groups in the Fibrinogen and PTT 
variables as was the case above (i.e. Bag 31 included). 
 
4.3.4.2 D-Dimers and PT 
 
The D-Dimers and PT variables were tested using the Van der Waerden’s transformation of 
the data and tested with a Two-way ANOVA, grouped for temperature and bag number, 
followed by a paired post hoc analysis using the Least Squares Difference (LSD). 
  
Tables of the statistics to follow can be viewed in Appendix A. 
 
As in the case where Bag 31 was included, significant differences occurred in both the D-
Dimers (P < 0.006) and PT (P < 0.000) variables. The D-Dimers showed a significant 
difference between the higher values of the 45°C and those in the 22°C, 37°C and 60°C 
groups. 
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In the case of the PT variables significant differences were observed between all 4 
temperature groups (P < 0.05), where the values in the 60°C group were higher than those in 
the 22°C which were higher than those in the 37°C which were higher than those in the 45°C 
group. 
 
We can conclude from the results of 4.3.3 and 4.3.4 that the statistically significant 
differences found between groups was not due to the outlier (Bag 31) but rather due to the 
temperature in which FFP was thawed. 
 
4.4 Analysis of r-values, Alpha Angles and Maximum Amplitude 
 
Statistics were done on each set of TEG results i.e. r-value 1 & r-value 2, Alpha angle 1 & 
Alpha angle 2, and MA 1 & MA 2 as well as on the calculated average of each value from 
each satellite bag i.e. R-value 1 & R-value 2, Alpha angle 1 & Alpha angle 2, and MA 1 & 
MA 2. 
 
Tables of all the statistical results pertaining to the TEG data analysis can be found in 
Appendix A. 
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4.4.1 Descriptive statistics of the variables grouped for temperature 
 
4.4.1.1 R-value 
 
The means in both R1 and R2 were higher in the 22ºC (18.13/12.4) and 60ºC (11.5/13.7) 
groups. The distribution, which seems to be similar in both the R1 and R2 groups, can be 
gauged from the Box and Whisker Plots in Figure 4.5 & 4.6 
 
4.4.1.2 Alpha Angle 
 
The means in both the Alpha Angle 1 and 2 were lower in the 60ºC group (26.2 / 26.08).  The 
mean in the 22ºC Alpha Angle 1 group (31.08) was also lower than the 37ºC (53.14) and 45ºC 
(53.78) group, but this wasn’t seen in the 22ºC group of Alpha Angle 2. See Figure 4.7 & 4.8 
 
4.4.1.3 Maximum Amplitude 
 
It is noticed once again that the means (12 / 11.6) in the 60ºC MA1 and MA 2 groups are 
lower than the means of the 22ºC (17.4 / 22.48), 37ºC (22.11 / 24.8) and 45ºC (22.3 / 22.1) 
groups.  See Figure 4.9 & 4.10 
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Figure 4.5: Box and Whisker Plot of r-value 1 
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Figure 4.6: Box and Whisker Plot of r-value 2 
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Figure 4.7: Box and Whisker Plot of Alpha Angle 1 
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Figure 4.8: Box and Whisker Plot of Alpha Angle 2 
60453722
Temperature (deg C)
30.00
25.00
20.00
15.00
10.00
5.00
0.00
M
ax
. A
m
pl
itu
de
 1
 
Figure 4.9: Box and Whisker Plot of MA 1 
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Figure 4.10: Box and Whisker Plot of MA 2 
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4.4.2 Test for normality of data in each variable 
 
The Kolmogorov-Smirnov test for normality was used.  The data for Alpha Angle 1 (P = 
0.946) and 2 (P = 0.716)), MA (1 (P = 0.133) and 2 (P = 0.207)) follow a normal distribution 
whereas the data for R-values (1 and 2) (P = 0.002 / P = 0.009) do not follow a normal 
distribution.   
 
In view of this a Two-way ANOVA, grouped for temperature and bag number, followed by a 
paired post hoc analysis using the Least Squares Difference (LSD), was used for Alpha Angle 
and MA, while a Two-way analysis on the Van der Waerden’s transformation of r values was 
used to analyse the r values. 
 
Tables of the statistics to follow can be viewed in Appendix A. 
 
4.5 Statistical testing for differences in each variable grouped for temperature 
 
4.5.1 R-value 1 and R-value 2 analysis 
 
The p values for R1 (P = 0.1904) and R2 (P = 0.6423) suggest no statistically significant 
differences in the means of R-values within the different temperature groups. 
  
4.5.2 Alpha Angle 1 and Alpha Angle 2 analysis 
 
A statistically significant difference was found within the Alpha Angle 1 (P = 0.004) and 
Alpha Angle 2 (P = 0.009) groups. 
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4.5.3 MA 1 and MA 2 analysis 
 
A statistically significant difference was found between the temperatures in both the MA 1 (P 
= 0.0056) and MA 2 (P = 0.0002). 
 
4.6 Statistical analysis comparing R1 and R2, AA1 and AA2 and MA1 and MA2 
 
Before continuing to determine which temperature groups were resulting in the statistical 
difference, I feel it is important to exclude a significant difference between R1 and R2, AA1 
and AA2 and MA1 and MA2.  A significant difference would suggest operator error or 
unreliable TEG equipment.  If no significant difference is found then an average of each of 
these groups, labeled R-value 1 & 2, Alpha angle 1 & 2 and MA 1& 2, will be analysed. 
 
Formula used for R-value 1 & 2, Alpha angle 1 & 2 and MA 1& 2 
R-value ĳ 1 & 2 = (R-valueĳ1 + R-valueĳ2)/2 
Alpha angle ĳ 1 & 2 = (Alpha angle ĳ1 + Alpha angle ĳ2)/2 
MA ĳ 1& 2 = (MA ĳ1 + MA ĳ2)/2 
 
The Wilcoxon Rank test for non-parametric data comparing pairs was used to compare the r 
values and a paired t-Test was used to asses the Alpha Angle and MA variables.   
 
No significant difference was found between R1 and R2 (P = 0.125), AA1 and AA2 (P = 
0.932) and MA1 and MA2 (P = 0.114).  
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4.6.1 Descriptive statistics for R-value 1 & 2, Alpha Angle 1 & 2 and MA 1 & 2, 
grouped for temperature 
 
In view there being no significant difference between R-value 1 and R-value 2, Alpha Angle 1 
and Alpha Angle 2, and MA 1 and MA 2, we now analyse the averages of these variables as 
explained above. 
 
4.6.1.1 R-value 1 & 2 
 
The mean values were higher in the 22ºC and 60ºC groups, with the 22ºC mean (16.3) being 
higher than the 60ºC mean (12.46). See Figure 4.11 
 
4.6.1.2 Alpha Angle 1 & 2 
 
The mean angle in 60ºC and 22ºC group were lower than in the 37ºC and 45ºC groups.  Again 
the 22ºC group (32.98) being lower than the 60ºC group (26.14). See Figure 4.12 
 
4.6.1.3 Maximum Amplitude 1 & 2 
 
The mean MA 1 & 2 in the 60ºC group (11.9) was lower than in the other 3 groups. See 
Figure 4.13 
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Figure 4.11: Box and Whisker Plot of r-value 1 & 2 
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Figure 4.12: Box and Whisker Plot of Alpha Angle 1 & 2 
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Figure 4.13: Box and Whisker Plot of MA 1 & 2 
 62
4.6.2 Test for normality of data in each variable 
 
The Kolmogorov-Smirnov test for normality was used.  The data for Alpha Angle 1 & 2, MA 
1 & 2 follow a normal distribution with P = 0.209 and P = 0.131 respectively, whereas the 
data for R-values 1 & 2 do not follow a normal distribution (P = 0.013).  In view of this a 
Two-way ANOVA, grouped for temperature and bag number, followed by a paired post hoc 
analysis using the Least Squares Difference (LSD), was used for Alpha Angle 1 & 2 and MA 
1 & 2, while a Two-way analysis on the Van der Waerden’s transformation of r values was 
used to analyse the r value 1 & 2. 
 
Tables of the statistics to follow can be viewed in Appendix A. 
 
4.6.3 Statistical testing for differences in each variable grouped for temperature 
 
4.6.3.1 R-value1 & 2 analysis 
 
The p values for R1 & 2 (P = 0.303) suggest no statistically significant differences in the 
means of the averaged R-values at different temperatures. 
 
4.6.3.2 Alpha Angle 1 & 2 analysis 
 
Using the Two-way ANOVA with Post Hoc analysis, a statistically significant difference was 
found in Alpha angle 1 & 2 (P = 0.002).  The differences are seen in the 37°C and 45°C 
groups when compared with the lower values in the 22°C and 60°C groups (P < 0.05).  The 
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values in the 37°C and 45°C groups are not significantly different from each other. The values 
in the 22°C and 60°C groups are likewise not significantly different from each other. 
  
4.6.3.3 MA 1 & 2 analysis 
 
Once again, using the Two-way ANOVA with Post Hoc analysis, a significant difference 
between the temperature groups in MA1 & 2 (P = 0.000) was found.  Post Hoc analysis 
revealed a statistically significant difference between the 37°C group when compared with the 
lower values in the 22°C and 60°C groups (P < 0.05). There was also a significant difference 
between the higher values in the 45°C group when compared with the 60°C group (P < 0.05). 
There was no significant difference between the 45°C and 22°C as well as between the 22°C 
and 60°C groups. 
  
4.7 Conclusion 
 
Chapter 4 gives a comprehensive analysis of the data obtained in this research project through 
a stepwise approach to the statistical tests used and the reasons for the use thereof.  
 
In summary, significant differences were seen between the 60°C group and the other 
temperature groups for fibrinogen (lower values in the 60°C group), PT and PTT (longer 
values in the 60°C group). Significant differences were also noted in the 60°C group when 
compared with the 37°C and 45°C groups in the Alpha Angle and MA data. This was also 
true for 22°C when compared with the 37°C and 45°C Alpha Angle and MA data, lower 
values in the 22°C and 60°C group. Significant differences were also between the 45°C group 
and the 22°C, 37°C and 60°C groups in the D Dimer and PT analyses, with the D Dimers in 
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the 45°C group being significantly higher and the PT being significantly shorter. Bag 31 was 
not found to be a cause of the findings in this study.  
 
Chapter 5 follows with a detailed discussion of the findings in this chapter. 
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CHAPTER FIVE 
DISCUSSION AND CONCLUSION 
 
5.1 Introduction 
 
This Chapter contains a detailed discussion around the statistical results of the laboratory 
work and the conclusion regarding the hypothesis of thawing FFP at high temperature causing 
clotting factor activation.  Following on this is a discussion on TEG versus conventional 
laboratory testing as well as the implications the study has on daily practice and future 
research. 
  
5.2 Discussion of statistical results 
 
Statistically significant differences were found in variables fibrinogen, D-Dimers, PTT, PT, 
Alpha Angle and Maximum Amplitude in the 60ºC temperature group compared with these 
variables in the 22ºC, 37ºC and 45ºC temperature groups.  
 
The mean fibrinogen level (1.72g/l) was significantly lower in the 60ºC group (P < 0.05).  PT 
(30.73sec) and PTT (50.38sec) was significantly prolonged in this group (P < 0.05), while the 
Alpha Angle and MA were significantly shallower and narrower respectively when compared 
with the 37ºC and 45ºC groups (P < 0.05), but not the 22ºC group.  The r value in the 60ºC 
group was prolonged when compared with the 37 ºC and 45ºC groups but not significantly so 
(P > 0.3). 
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The findings of low fibrinogen levels suggest clotting factor depletion. This is further 
corroborated by prolongation of the PT and PTT.  A prolonged r value (albeit not significant), 
shallow Alpha Angle and narrow MA further suggest factor depletion with little factor 
activity. The most striking finding in this study is the significant difference seen in clotting 
factor activity, or rather inactivity, and factor depletion in FFP thawed at 60ºC. The most 
likely explanation for this would be protein denaturation when FFP is thawed at 60ºC. 
 
There is, however, evidence to suggest factor activation at 45ºC. Significant differences were 
found in D-Dimers in the 45ºC group when compared with the other 3 temperature groups (P 
< 0.05).  The mean D-Dimers in the 45ºC group was 0.59*10^2ng/l which is extraordinarily 
high. As an example, a D-Dimers of greater than 0.5*10^2ng/l is indicative of a deep vein 
thrombosis in clinical practice. 
 
D-Dimers are produced through fibrinolysis. Fibrin is formed through the activation of 
thrombin which in turn is usually activated as the last step in the coagulation pathway. Hence 
elevated D-Dimers imply, at least, thrombin activation and fibrin formation. 
 
Of further interest are the PT results. A significant difference between the PT of the 45ºC and 
those of the 22ºC and 37ºC groups was found (P < 0.05). The mean PT of the 45ºC (13.974 
sec) group was shorter than the in the 22ºC (15.55 sec) and 37ºC (14.718 sec) groups. The 
faster time to coagulation further suggest clotting factor activation at this temperature.  
 
D-Dimers in the 60ºC group (mean = 0.213*10^2ng/l) were non-significantly elevated when 
compared with 22ºC (0.157*10^2ng/l) and 37ºC (0.183*10^2ng/l). This may suggest a higher 
level of thrombin formation and hence fibrin production during the thawing process, again 
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suggesting the possibility of factor activation in FFP thawed at high temperatures. Statistically, 
however, this may also be due to random variation. 
 
This study has confirmed the findings of previous research of clotting factor depletion in FFP 
thawed at 60ºC temperatures (4,5,6).  This study is the only study to show clotting factor 
activation at a modest thawing temperature of 45ºC and possibly even at 60ºC. The study 
done by Plotz and Ciotola did not find any differences in clotting factor assay in FFP thawed 
at 37ºC  and 45ºC (4). They concluded that thawing FFP at 45ºC was quicker and safe. The 
parameters they measured were PT, PTT, fibrinogen and Factor VIII assay, and as in our 
study, no significant differences were detected between the 37ºC and 45ºC groups at the 5% 
level of significance, in contrast to our study where there was statistically significant 
difference in PT in FFP thawed at 45ºC. Small sample size and the fact the laboratory work in 
the study by Plotz was performed on samples that were kept on ice after thawing, as opposed 
to this study where samples were tested immediately after thawing, may account for these 
differences in findings. 
 
The TEG results showed significant differences in the 37ºC and 45ºC groups when compared 
with the 60ºC group in Alpha Angle and MA (P < 0.05), and in the 22ºC group when 
compared with the 37ºC and 45ºC groups for Alpha Angle and 37ºC group for MA  (P < 0.05). 
No significant differences were found in r values. The 22ºC variables closely match the 60ºC 
variables with longer r values, narrower Alpha Angles and MA. This suggests that factor 
inactivity occurs in FFP thawed at 22ºC, bearing in mind however, that the only significant 
differences found were between this group and 37ºC and 45ºC groups for Alpha Angle and 
37ºC for MA. Supporting this are the prolonged PT and PTT results found in this group which 
were not statistically significantly different from the 37ºC and 45ºC groups except when Bag 
 68
31 was excluded in the analyses. When Bag 31 was excluded, a significant difference was 
seen in the PT between the 4 temperature groups, with the PT in the 45ºC group < 37ºC group 
< 22ºC group < 60ºC group (P < 0.05). 
 
Clotting factors and enzymes needed for cleavage, activation and clot formation are proteins 
which normally function at 37ºC.  Therefore, at 22ºC the hypothermia may partially or 
completely inhibit the clotting cascade. This would explain the findings of delayed clotting. 
An argument against this theory would be the fact that TEG samples are kept at 37ºC during 
the test itself negating the effect of 22ºC hypothermia on the FFP. 
 
There were no comparative studies testing FFP thawed at this temperature. 
 
In summary, the findings of this study prove the alternate hypothesis that high thawing 
temperature is associated with clotting factor activation. This was evident at a temperature of 
45ºC. FFP thawed at 60ºC was associated with delayed clot formation possibly on the basis of 
denatured proteins and may also have had factor activation as evidenced by a non significant 
elevation in D-Dimers at 60ºC. FFP thawed at 22ºC is dysfunctional and may need to be 
warmed to ‘body temperature’ to become more functional. The implications of these findings 
follow. 
 
5.3 TEG versus conventional laboratory tests 
 
TEG is a dynamic global measure of clotting factor interactions and hence coagulation, rather 
than a test of specific parts of the coagulation pathway, as are the conventional tests of 
coagulation. 
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The fibrinogen, PT and PTT provided clear evidence of clotting factor inactivation in FFP 
thawed at 60ºC, explaining and complimenting the significant findings of prolonged Alpha 
Angle and MA in this group. This was also suggested by a non-significant, longer r value in 
the 60ºC group. The D-Dimers and PT provided evidence of clotting factor activation in FFP 
thawed at 45ºC and possibly at 60ºC too, which was not detected, with TEG. The TEG, 
however, alludes to factor inactivation at 22ºC which would not have been evident using the 
conventional tests alone.  
 
The TEG therefore, provides a more global dynamic overview of the coagulation process 
while the conventional tests provided a more specific analysis of parts of the coagulation 
pathway. Both TEG and conventional tests of coagulation were found to be relevant and 
complementary in this study. 
 
5.4 Implications for daily practice 
 
As elaborated on in Chapter 1, section 1.2, the current practice in South Africa, as regards 
thawing FFP is not standardised. Although the SABTS current recommendation is to thaw 
FFP in a water bath at 37ºC, this is often not followed and many techniques of thawing FFP 
are used in this country including: the use of non sterile water environment with unmeasured 
water temperatures ranging from cold to hot and microwave ovens either conventional or 
specifically designed.  
 
FFP thawed at higher temperatures leads to clotting factor inactivation most likely on the 
basis of protein denaturation. This study also found evidence suggesting clotting factor 
activation. These findings are again cause for concern not only because of the potential of a 
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SIRS response and DIC from activated clotting factors but also because denatured proteins 
themselves could induce an inflammatory response, cause arteriolar obstruction with tissue 
ischaemia, of particular concern in kidney and lung parenchyma with the concomitant organ 
dysfunction and failure. This is not withstanding the obvious loss of clotting factor function in 
FFP thawed at these temperatures, defeating the purpose for which it was needed in the first 
place. 
 
FFP thawed at 22ºC was shown to be significantly non-functional or inactivated. FFP thawed 
at this temperature may become functional at body temperature but this was not evident in 
TEG samples, which as already mentioned, are preheated to 37ºC. Thawing at 22ºC poses two 
problems of a) inactive FFP which may or may not become functional once warmed up and b) 
administering cold fluid to a patient who may be at risk for hypothermia already, as is the case 
in major surgery or trauma. Hypothermia per se is associated with increased bleeding from 
impaired coagulation further placing these patients at risk of coagulopathy and DIC. 
 
Because this study was performed with meticulous attention to SOP for the various laboratory 
tests used and the validity of these tests to identify activation and function of the coagulation 
pathways, this study gives reliable credence to the its findings and hence we enable valuable 
and informed suggestions to be made with regards to the daily practicalities of FFP use. 
 
Based on these findings it is recommended that FFP be thawed at temperatures of no greater 
than 37ºC to avoid activation and possible denaturation at higher temperatures, and the 
associated potential for complications. Furthermore FFP should not be thawed at temperatures 
that are too cold because of the risk of inactivated clotting factors as well as induced 
hypothermia in the patient. The optimal temperature for thawing is 37ºC. 
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Where FFP is needed urgently, facilities should be available to thaw the FFP in an appropriate 
and safe microwave oven. In South Africa, cost constraints is an important factor in service 
delivery yet clinicians are plagued and inundated by an inordinate amount of trauma often 
urgently requiring blood products. In view of this each blood bank which services a hospital 
which treats patients requiring emergency surgery, and possibly FFP urgently, should be in 
possession of a microwave oven specifically designed to thaw FFP, and issue the requested 
FFP in a thawed state. 
 
FFP that is not required urgently could still be thawed in a waterbath at 37ºC but protected by 
a sterile packet or thawed in a sterile water bath to avoid the potential risk of bacterial 
contamination. Based on the findings in this study, the SABTS now supply, on request, FFP 
which has been thawed in a sterile waterbath at 37ºC. 
 
FFP should be stored in appropriate refrigerators capable of reaching -25ºC. Conventional 
refrigerators run at temperatures +/- -8ºC and this may not be adequate for storage of FFP 
which has been issued but not used, for example, emergency stock which is kept in the 
operating theater complex for emergency situations. 
 
5.5 Implications for further research 
 
To date no study, that we are aware of, has used TEG analysis on FFP. This study therefore 
proposes the 37ºC TEG results to be used as normal values for future research. The reference 
ranges proposed are derived from the 95% confidence interval for each variable, r value, 
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Alpha Angle and Maximum Amplitude, of the FFP thawed at 37°C, and is tabulated in Table 
5.1 
 
Table 5.1: Proposed normal TEG values for FFP 
 Mean Normal reference range 
R value 8.5 minutes 4.82 – 12.21 minutes 
Alpha Angle 53.09 ° 48.08 – 59.15 ° 
Maximum Amplitude 23.49 mm 20.57 – 24.60 mm 
 
 
5.6 Conclusion and summary 
 
This chapter reviewed and discussed the statistical analysis of the data collected. Statistical 
analysis of the FFP thawed at different temperatures suggests that FFP thawed at high 
temperatures activates and or denatures clotting factors. FFP thawed at 22ºC is relatively non-
functional and may have other adverse side effects when administered. Therefore it is 
recommended that FFP be thawed at 37ºC.  
 
The study therefore proves the hypothesis that FPP thawed at high thawing temperatures 
activates the factors therein. 
 
Because the data collected was rigorous, reliable and valid, the findings and hence 
implications, for the thawing of FFP in South Africa are very important and relevant. 
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TEG was founded to be a useful technique in the qualitative analysis of FFP. Further to the 
hypothesis of the study I propose that the TEG values of FFP thawed at 37ºC in this study, be 
used as normal reference ranges for FFP undergoing TEG analysis in the future.  
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APPENDIX A 
 
TABLES AND GRAPHS OF STATISTICAL TESTS 
 
 
1. Tables of statistical results of data obtained from ‘conventional’ coagulation testing 
 
 
 
Table A.1: Kolmogorov-Smirnov test for Fibrinogen, D-Dimers, PTT and PT (including 
bag 31) 
 
  Fibrinogen D-Dimers PTT PT 
N 40 40 40 39
Normal 
Parameters(a,b) 
Mean 3.6375 .2866 37.0125 18.8474
  Std. Deviation 1.54765 .29452 15.70617 17.20093
Most Extreme 
Differences 
Absolute .142 .310 .249 .415
  Positive .066 .310 .249 .415
  Negative -.142 -.204 -.181 -.365
Kolmogorov-Smirnov Z .897 1.962 1.576 2.590
Asymp. Sig. (2-tailed) .397 .001 .014 .000
a  Test distribution is Normal. 
b  Calculated from data. 
 
 
 
 
Table A.2: Kolmogorov-Smirnov test for Fibrinogen, D-Dimers, PTT and PT (excluding 
bag 31) 
One-Sample Kolmogorov-Smirnov Test
39 39 39 38
3.7308 .2916 34.8846 16.1855
1.44953 .29665 8.20326 4.47828
.129 .310 .089 .277
.068 .310 .089 .277
-.129 -.200 -.069 -.232
.808 1.936 .556 1.708
.531 .001 .917 .006
N
Mean
Std. Deviation
Normal Parametersa,b
Absolute
Positive
Negative
Most Extreme
Differences
Kolmogorov-Smirnov Z
Asymp. Sig. (2-tailed)
Fibrinogen D-Dimers PTT PT
Test distribution is Normal.a. 
Calculated from data.b. 
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Figure A1: P-P Plot of Fibrinogen (including bag 31) 
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Figure A2: P-P Plot of D-Dimers (including bag 31) 
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Figure A3: P-P Plot of PTT (including bag 31) 
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Figure A4: P-P Plot of PT (including bag 31) 
 
 
 
Table A.3: ANOVA test of Fibrinogen 
 
Source     DF        SS        MS       F        P
BAG         9   33.6352    3.7372    9.62   0.0000 
TEMPERAT    3   49.2945   16.4315   42.32   0.0000 
Error      27   10.4838    0.3883 
Total      39   93.4135 
 
Grand Mean 3.6375    CV 17.13 
 
Tukey's 1 Degree of Freedom Test for Nonadditivity 
Source          DF        SS        MS       F        P
Nonadditivity    1    0.0149   0.01486    0.04   0.8492 
Remainder       26   10.4690   0.40265
 
 
 
Table A.4: Post-Hoc analysis of Fibrinogen 
 
LSD All-Pairwise Comparisons Test of FIBRINOGEN for TEMPERATURE 
 
TEMPERATURE    Mean  Homogeneous Groups 
      37  4.4130  A 
      45  4.2750  A 
      22  4.1400  A 
      60  1.7220   B 
 
Alpha              0.05     Standard Error for Comparison  0.2787 
Critical T Value  2.052     Critical Value for Comparison  0.5718 
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Table A.5: Analysis of variance of the Van der Waerden transformation of D-Dimers 
 
Source     DF        SS        MS      F        P
BAG         9   2764.63   307.181   5.43   0.0003 
TEMPERAT    3    996.35   332.117   5.87   0.0032 
Error      27   1528.03    56.594 
Total      39   5289.00 
 
Grand Mean 20.500    CV 36.70 
 
Tukey's 1 Degree of Freedom Test for Nonadditivity 
Source          DF        SS        MS       F        P
Nonadditivity    1     20.62   20.6226    0.36   0.5561 
Remainder       26   1507.40   57.9770
 
 
Table A.6: Post-Hoc analysis of D-Dimers 
 
LSD All-Pairwise Comparisons Test of D-Dimers for TEMPERATURE 
TEMPERAT    Mean  Homogeneous Groups 
      45  29.050  A 
      60  18.850   B 
      22  17.100   B 
      37  17.000   B 
 
Alpha              0.05     Standard Error for Comparison  3.3643 
Critical T Value  2.052     Critical Value for Comparison  6.9030 
 
 
Table A.7: Analysis of variance of the Van der Waerden transformation of PTT 
 
Source     DF        SS        MS       F        P
BAG         9   3110.50   345.611   12.90   0.0000 
TEMPERAT    3   1495.00   498.333   18.60   0.0000 
Error      27    723.50    26.796 
Total      39   5329.00 
 
Grand Mean 20.500    CV 25.25 
 
Tukey's 1 Degree of Freedom Test for Nonadditivity 
Source          DF        SS        MS       F        P
Nonadditivity    1    12.324   12.3242    0.45   0.5080 
Remainder       26   711.176   27.3529
 
 
Table A.8: Post-Hoc analysis of PTT 
 
LSD All-Pairwise Comparisons Test of PTT for TEMPERATURE
 
TEMPERATURE    Mean  Homogeneous Groups 
      60  30.900  A 
      45  18.300   B 
      37  17.600   B 
      22  15.200   B 
 
Alpha              0.05     Standard Error for Comparison  2.3150 
Critical T Value  2.052     Critical Value for Comparison  4.7500 
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Table A.9: Analysis of variance of the Van der Waerden transformation of PT 
 
Source     DF        SS        MS       F        P
BAG         9    962.63   106.959    2.69   0.0232 
TEMPERAT    3   2970.00   990.000   24.94   0.0000 
Error      26   1032.17    39.699 
Total      38 
 
Note: SS are marginal (type III) sums of squares 
 
Grand Mean 19.794    CV 31.83 
 
 
 
Table A.10: Post-Hoc analysis of PT 
 
LSD All-Pairwise Comparisons Test of PT for TEMPERATURE
 
TEMPERATURE    Mean  Homogeneous Groups 
      60  32.850  A 
      22  21.350   B 
      37  15.628   B 
      45   9.350    C 
 
Alpha              0.05     Standard Error for Comparison  VARIES 
Critical T Value  2.056     Critical Value for Comparison  VARIES 
 
 
 
Table A.11: ANOVA test of Fibrinogen, Bag 31 excluded 
 
Source     DF        SS        MS       F        P
BAG         9   30.6498    3.4055    8.70   0.0000 
TEMPERAT    3   42.0989   14.0330   35.86   0.0000 
Error      26   10.1744    0.3913 
Total      38 
 
Note: SS are marginal (type III) sums of squares 
 
Grand Mean 3.6544    CV 17.12 
 
Tukey's 1 Degree of Freedom Test for Nonadditivity 
Source          DF        SS        MS       F        P
Nonadditivity    1   0.17943   0.17943    0.45   0.5090 
Remainder       25   9.99499   0.39980
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Table A.12: Post-Hoc analysis of Fibrinogen, Bag 31 excluded 
 
LSD All-Pairwise Comparisons Test of FIBRINOGEN for TEMPERATURE 
 
TEMPERATURE    Mean  Homogeneous Groups 
      37  4.4130  A 
      45  4.2750  A 
      22  4.1400  A 
      60  1.7897   B 
 
Alpha              0.05     Standard Error for Comparison  VARIES 
Critical T Value  2.056     Critical Value for Comparison  VARIES 
 
 
 
Table A.13: Analysis of variance of the Van der Waerden transformation of D-Dimers, 
Bag 31 excluded 
 
Source     DF        SS        MS      F        P
BAG         9   2540.16   282.240   4.87   0.0007 
TEMPERAT    3    978.39   326.129   5.62   0.0041 
Error      26   1507.47    57.980 
Total      38 
 
Note: SS are marginal (type III) sums of squares 
 
Grand Mean 20.638    CV 36.90 
 
Tukey's 1 Degree of Freedom Test for Nonadditivity 
Source          DF        SS        MS       F        P
Nonadditivity    1     19.52   19.5198    0.33   0.5720 
Remainder       25   1487.95   59.5180
 
 
 
 
Table A.14: Post-Hoc analysis of D-Dimers, Bag 31 excluded 
 
LSD All-Pairwise Comparisons Test of D-Dimers for TEMPERATURE 
 
TEMPERATURE    Mean  Homogeneous Groups 
      45  29.050  A 
      60  19.402   B 
      22  17.100   B 
      37  17.000   B 
 
Alpha              0.05     Standard Error for Comparison  VARIES 
Critical T Value  2.056     Critical Value for Comparison  VARIES 
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Table A.15: ANOVA test of PTT, Bag 31 excluded 
 
Source     DF        SS        MS      F        P
BAG         9   1243.61   138.179   6.03   0.0001 
TEMPERAT    3    655.70   218.567   9.54   0.0002 
Error      26    595.73    22.913 
Total      38 
 
Note: SS are marginal (type III) sums of squares 
 
Grand Mean 34.996    CV 13.68 
 
Tukey's 1 Degree of Freedom Test for Nonadditivity 
Source          DF        SS        MS       F        P
Nonadditivity    1    45.294   45.2936    2.06   0.1639 
Remainder       25   550.436   22.0174
 
 
 
Table A.16: Post-Hoc analysis of PTT, Bag 31 excluded 
 
LSD All-Pairwise Comparisons Test of PTT for TEMPERATURE
 
TEMPERATURE    Mean  Homogeneous Groups 
      60  42.312  A 
      45  33.230   B 
      37  32.790   B 
      22  31.650   B 
 
Alpha              0.05     Standard Error for Comparison  VARIES 
Critical T Value  2.056     Critical Value for Comparison  VARIES 
 
 
 
Table A.17: Analysis of variance of the Van der Waerden transformation of PT, Bag 31 
excluded 
 
Source     DF        SS        MS       F        P
BAG         9   1087.27   120.808    3.49   0.0064 
TEMPERAT    3   2432.50   810.833   23.42   0.0000 
Error      25    865.50    34.620 
Total      37 
 
Note: SS are marginal (type III) sums of squares 
 
Grand Mean 19.239    CV 30.58 
 
Tukey's 1 Degree of Freedom Test for Nonadditivity 
Source          DF        SS        MS      F        P
Nonadditivity    1    14.087   14.0871    0.40   0.5345 
Remainder       24   851.413   35.4755
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Table A.18: Post-Hoc analysis of PT, Bag 31 excluded 
 
LSD All-Pairwise Comparisons Test of PT for TEMPERATURE
 
TEMPERATURE    Mean  Homogeneous Groups 
      60  31.183  A 
      22  21.350   B 
      37  15.072    C 
      45   9.350     D 
 
Alpha              0.05     Standard Error for Comparison  VARIES 
Critical T Value  2.060     Critical Value for Comparison  VARIES 
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2. Tables of statistical results for data obtained from TEG testing 
 
 
Table A.19: Table of descriptive statistics of r value 1 
Descriptives
18.1333 8.69198
-4.2101
40.4768
16.5037
9.7000
453.303
21.29091
4.80
60.80
8.0600 1.05158
5.6812
10.4388
7.9167
7.5500
11.058
3.32539
3.90
14.80
6.5667 .56001
5.2753
7.8581
6.5685
7.0000
2.823
1.68003
4.20
8.90
11.5600 3.12258
4.4962
18.6238
11.1667
8.3500
97.505
9.87446
.20
30.00
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Temperature (deg C)
22
37
45
60
R value 1
Statistic Std. Error
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Table A.20: Table of descriptive statistics of r value 2 
 
Descriptives
12.4000 3.33706
3.8218
20.9782
12.0833
10.0000
66.816
8.17411
4.10
26.40
8.9700 2.31718
3.7282
14.2118
8.1778
6.3000
53.693
7.32758
3.90
28.30
8.9667 1.14758
6.3203
11.6130
8.8185
8.8000
11.853
3.44275
4.20
16.40
13.3700 3.44216
5.5833
21.1567
12.9944
8.0500
118.485
10.88506
3.50
30.00
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Temperature (deg C)
22
37
45
60
R value 2
Statistic Std. Error
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Table A.21: Table of descriptive statistics of Alpha Angle 1 
 
Descriptives
31.0833 7.95916
10.6237
51.5430
31.5815
36.1000
380.090
19.49589
.00
53.20
53.1400 5.19301
41.3926
64.8874
53.5000
57.1500
269.674
16.42175
24.50
75.30
53.7889 2.94809
46.9906
60.5872
53.9599
54.3000
78.221
8.84427
36.90
67.60
26.2100 7.68237
8.8313
43.5887
24.8167
26.2500
590.188
24.29378
.00
77.50
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Temperature (deg C)
22
37
45
60
Alpha Angle 1
Statistic Std. Error
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Table A.22: Table of descriptive statistics of Alpha Angle 2 
 
Descriptives
41.2500 5.49465
27.1256
55.3744
41.1167
38.9500
181.147
13.45909
25.10
59.80
53.0300 5.84483
39.8081
66.2519
54.0500
55.4500
341.620
18.48297
12.30
75.40
49.2556 3.97454
40.0902
58.4209
49.2617
47.7000
142.173
11.92362
32.60
65.80
26.0800 7.32442
9.5110
42.6490
25.7389
25.5500
536.471
23.16184
.00
58.30
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Temperature (deg C)
22
37
45
60
Alpha Angle 2
Statistic Std. Error
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Table A.23: Table of descriptive statistics of MA 1 
 
Descriptives
17.4500 4.51344
5.8478
29.0522
17.8389
21.9500
122.227
11.05563
.00
27.90
22.1100 1.24744
19.2881
24.9319
22.1722
22.8000
15.561
3.94474
15.90
27.20
22.3111 .90882
20.2154
24.4069
22.3179
22.3000
7.434
2.72646
17.90
26.60
12.1800 2.84628
5.7413
18.6187
12.2556
15.4500
81.013
9.00072
.00
23.00
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Temperature (deg C)
22
37
45
60
Max. Amplitude 1
Statistic Std. Error
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Table A.24: Table of descriptive statistics of MA 2 
 
Descriptives
22.4833 1.82965
17.7801
27.1866
22.4593
22.8000
20.086
4.48170
17.10
28.30
24.8600 3.23866
17.5336
32.1864
23.8278
23.0000
104.889
10.24155
15.90
52.40
22.1667 1.09202
19.6485
24.6849
22.1519
22.3000
10.733
3.27605
18.00
26.60
11.6700 2.90968
5.0878
18.2522
11.7000
12.7500
84.662
9.20121
.00
22.80
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Temperature (deg C)
22
37
45
60
Max. Amplitude 2
Statistic Std. Error
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Table A.25: Kolmogorov-Smirnov test for r value 1, r value 2, Alpha Angle 1, Alpha 
Angle 2, MA 1 and MA 2 
One-Sample Kolmogorov-Smirnov Test
35 35 35 35 35 35
10.4029 10.8143 41.8314 42.3400 18.5257 19.9914
10.60723 7.90317 21.66866 20.41491 8.05647 9.23801
.311 .279 .089 .118 .197 .180
.311 .279 .071 .079 .122 .180
-.241 -.177 -.089 -.118 -.197 -.177
1.842 1.650 .525 .697 1.164 1.065
.002 .009 .946 .716 .133 .207
N
Mean
Std. Deviation
Normal Parametersa,b
Absolute
Positive
Negative
Most Extreme
Differences
Kolmogorov-Smirnov Z
Asymp. Sig. (2-tailed)
R value 1 R value 2 Alpha Angle 1 Alpha Angle 2
Max.
Amplitude 1
Max.
Amplitude 2
Test distribution is Normal.a. 
Calculated from data.b. 
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Figure A5: P-P Plot of r value 1 
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Figure A6: P-P Plot of r value 2 
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Figure A7: P-P Plot of Alpha Angle 1 
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Figure A8: P-P Plot of Alpha Angle 2 
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Figure A9: P-P Plot of MA 1 
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Figure A10: P-P Plot of MA 2 
 
 
Table A.26: Analysis of variance of the Van der Waerden transformation of r value 1 
 
Source     DF        SS        MS      F        P
BAG         9   1359.01   151.001   1.76   0.1366 
TEMPERAT    3    446.19   148.731   1.74   0.1904 
Error      21   1799.64    85.697 
Total      33 
 
Note: SS are marginal (type III) sums of squares 
 
Grand Mean 18.856    CV 49.09 
 
Tukey's 1 Degree of Freedom Test for Nonadditivity 
Source          DF        SS        MS       F        P
Nonadditivity    1      0.10    0.0983    0.00   0.9740 
Remainder       20   1799.54   89.9771
 
 
 
Table A.27: Analysis of variance of the Van der Waerden transformation of r value 2 
 
Source     DF        SS        MS      F        P
BAG         9    778.24    86.472   0.69   0.7075 
TEMPERAT    3    212.46    70.821   0.57   0.6423 
Error      21   2619.24   124.726 
Total      33 
 
Note: SS are marginal (type III) sums of squares 
 
Grand Mean 18.715    CV 59.68 
 
Tukey's 1 Degree of Freedom Test for Nonadditivity 
Source          DF        SS        MS      F        P
Nonadditivity    1     10.51    10.509    0.08   0.7794 
Remainder       20   2608.74   130.437
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Table A.28: ANOVA test of Alpha Angle 1 
 
Source     DF        SS        MS      F        P
BAG         9   3398.81    377.65   1.21   0.3380 
TEMPERAT    3   5512.14   1837.38   5.89   0.0041 
Error      22   6866.16    312.10 
Total      34 
 
Note: SS are marginal (type III) sums of squares 
 
Grand Mean 39.765    CV 44.43 
 
Tukey's 1 Degree of Freedom Test for Nonadditivity 
Source          DF        SS        MS       F        P
Nonadditivity    1    343.44   343.441    1.11   0.3050 
Remainder       21   6522.72   310.606
 
 
 
Table A.29: ANOVA test of Alpha Angle 2 
 
Source     DF        SS        MS      F        P
BAG         9   3366.20    374.02   1.25   0.3165 
TEMPERAT    3   4414.27   1471.42   4.92   0.0092 
Error      22   6579.73    299.08 
Total      34 
 
Note: SS are marginal (type III) sums of squares 
 
Grand Mean 42.854    CV 40.36 
 
Tukey's 1 Degree of Freedom Test for Nonadditivity 
Source          DF        SS        MS       F        P
Nonadditivity    1    325.12   325.120    1.09   0.3080 
Remainder       21   6254.61   297.839
 
 
 
Table A.30: ANOVA test of MA 1 
Source     DF        SS        MS      F        P
BAG         9   681.118    75.680   1.94   0.0989 
TEMPERAT    3   645.653   215.218   5.51   0.0056 
Error      22   858.651    39.030 
Total      34 
 
Note: SS are marginal (type III) sums of squares 
 
Grand Mean 17.880    CV 34.94 
 
Tukey's 1 Degree of Freedom Test for Nonadditivity 
Source          DF        SS        MS       F        P
Nonadditivity    1   194.093   194.093    6.13   0.0219 
Remainder       21   664.559    31.646
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Table A.31: ANOVA test of MA 2 
 
Source     DF        SS        MS       F        P
BAG         9   1195.13   132.792    4.19   0.0029 
TEMPERAT    3    985.66   328.555   10.37   0.0002 
Error      22    697.13    31.688 
Total      34 
 
Note: SS are marginal (type III) sums of squares 
 
Grand Mean 20.026    CV 28.11 
 
Tukey's 1 Degree of Freedom Test for Nonadditivity 
Source          DF        SS        MS       F        P
Nonadditivity    1    27.957   27.9569    0.88   0.3596 
Remainder       21   669.169   31.8652
 
 
 
Table A.32: Wilcoxon Rank Test comparing r value 1 and r value 2, AA 1 and AA 2, 
MA 1 and MA 2 
Ranks
11a 14.36 158.00
19b 16.16 307.00
3c
33
16d 16.16 258.50
16e 16.84 269.50
1f
33
16g 11.63 186.00
13h 19.15 249.00
4i
33
Negative Ranks
Positive Ranks
Ties
Total
Negative Ranks
Positive Ranks
Ties
Total
Negative Ranks
Positive Ranks
Ties
Total
R value 2 - R value 1
Alpha Angle 2 -
Alpha Angle 1
Max. Amplitude 2 -
Max. Amplitude 1
N Mean Rank Sum of Ranks
R value 2 < R value 1a. 
R value 2 > R value 1b. 
R value 2 = R value 1c. 
Alpha Angle 2 < Alpha Angle 1d. 
Alpha Angle 2 > Alpha Angle 1e. 
Alpha Angle 2 = Alpha Angle 1f. 
Max. Amplitude 2 < Max. Amplitude 1g. 
Max. Amplitude 2 > Max. Amplitude 1h. 
Max. Amplitude 2 = Max. Amplitude 1i. 
 
Test Statisticsb
-1.533a -.103a -.681a
.125 .918 .496
Z
Asymp. Sig. (2-tailed)
R value 2 -
R value 1
Alpha Angle
2 - Alpha
Angle 1
Max.
Amplitude 2
- Max.
Amplitude 1
Based on negative ranks.a. 
Wilcoxon Signed Ranks Testb. 
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Table A.33: Table of descriptive statistics of r value 1 & 2 
 
Descriptives
16.3000 5.16423
1.9618
30.6382
15.9917
12.1500
133.346
11.54756
4.45
33.70
8.5150 1.63163
4.8240
12.2060
8.0472
7.4500
26.622
5.15968
3.90
21.55
7.8313 .87433
5.7638
9.8987
7.7653
7.2000
6.116
2.47299
4.20
12.65
12.4650 3.03114
5.6081
19.3219
12.0028
8.2000
91.878
9.58532
3.95
29.30
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Temperature (deg C)
22
37
45
60
Means of R 1& 2
Statistic Std. Error
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Table A.34: Table of descriptive statistics of Alpha Angle 1 & 2 
 
Descriptives
32.9800 6.47778
14.9948
50.9652
32.8111
29.4500
209.808
14.48476
16.20
52.80
53.0850 4.95238
41.8819
64.2881
53.7944
50.6000
245.261
15.66082
18.40
75.00
53.6188 2.34037
48.0847
59.1528
53.5069
54.4750
43.819
6.61956
45.60
63.65
26.1450 7.28724
9.6601
42.6299
25.4944
25.9000
531.039
23.04429
.00
64.00
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Temperature (deg C)
22
37
45
60
Means of Aplha 1 & 2
Statistic Std. Error
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Table A.35: Table of descriptive statistics of MA 1 & 2 
 
Descriptives
19.4000 2.83262
11.5354
27.2646
19.3806
22.2000
40.119
6.33394
12.40
26.75
23.4850 2.08141
18.7765
28.1935
23.0222
22.6500
43.323
6.58201
15.90
39.40
22.5813 .85215
20.5662
24.5963
22.5819
22.0750
5.809
2.41024
18.55
26.60
11.9250 2.85103
5.4755
18.3745
11.9778
14.3750
81.283
9.01573
.00
22.90
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Mean
Lower Bound
Upper Bound
95% Confidence
Interval for Mean
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Temperature (deg C)
22
37
45
60
Means of MA 1 & 2
Statistic Std. Error
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Table A.36: Kolmogorov-Smirnov test for R value 1 & 2, Alpha Angle 1 & 2, MA 1 & 2 
One-Sample Kolmogorov-Smirnov Test
33 33 33
10.7258 42.0045 19.1439
7.79465 20.43436 8.15288
.277 .185 .203
.277 .068 .145
-.191 -.185 -.203
1.592 1.063 1.168
.013 .209 .131
N
Mean
Std. Deviation
Normal Parameters a,b
Absolute
Positive
Negative
Most Extreme
Differences
Kolmogorov-Smirnov Z
Asymp. Sig. (2-tailed)
Means of
R 1& 2
Means of
Aplha 1 & 2
Means of
MA 1 & 2
Test distribution is Normal.a. 
Calculated from data.b. 
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Figure A11: P-P Plot of r value 1 & 2 
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Figure A12: P-P Plot of Alpha Angle 1 & 2 
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Figure A13: P-P Plot of MA 1 & 2 
 
 
Table A.37: Analysis of variance of the Van der Waerden transformation of r value 1 & 
2 
 
Source     DF        SS        MS      F        P
BAG         9   1239.66   137.740   1.83   0.1286 
TEMPERAT    3    294.66    98.219   1.30   0.3025 
Error      19   1432.43    75.391 
Total      31 
 
Note: SS are marginal (type III) sums of squares 
 
Grand Mean 17.750    CV 48.92 
 
 
Tukey's 1 Degree of Freedom Test for Nonadditivity 
Source          DF        SS        MS       F        P
Nonadditivity    1      0.06    0.0636    0.00   0.9778 
Remainder       18   1432.36   79.5758
 
 
 
Table A.38: Post-Hoc analysis of r value 1 & 2 
 
LSD All-Pairwise Comparisons Test of r value 1 & 2 for TEMPERATURE 
 
TEMPERATURE    Mean  Homogeneous Groups 
      22  22.528  A 
      60  19.373  A 
      45  14.850  A 
      37  14.250  A 
 
Alpha              0.05     Standard Error for Comparison  VARIES 
Critical T Value  2.093     Critical Value for Comparison  VARIES 
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Table A.39: ANOVA test of Alpha Angle 1 & 2 
 
Source     DF        SS        MS      F        P
BAG         9   3476.78    386.31   1.66   0.1653 
TEMPERAT    3   5149.43   1716.48   7.37   0.0016 
Error      20   4655.89    232.79 
Total      32 
 
Note: SS are marginal (type III) sums of squares 
 
Grand Mean 41.051    CV 37.17 
 
Tukey's 1 Degree of Freedom Test for Nonadditivity 
Source          DF        SS        MS       F        P
Nonadditivity    1    410.54   410.544    1.84   0.1912 
Remainder       19   4245.34   223.439
 
 
 
Table A.40: Post-Hoc analysis of Alpha Angle 1 & 2 
LSD All-Pairwise Comparisons Test of ALPHA ANGLE 1 & 2 for TEMPERATURE 
 
TEMPERATURE    Mean  Homogeneous Groups 
      45  53.191  A 
      37  53.085  A 
      22  31.841   B 
      60  25.687   B 
 
Alpha              0.05     Standard Error for Comparison  VARIES 
Critical T Value  2.093     Critical Value for Comparison  VARIES 
 
 
 
Table A.41: ANOVA test of MA 1 & 2 
Source     DF        SS        MS      F        P
BAG         9   737.508    81.945   2.80   0.0264 
TEMPERAT    3   786.662   262.221   8.96   0.0006 
Error      20   585.088    29.254 
Total      32 
 
Note: SS are marginal (type III) sums of squares 
 
Grand Mean 18.644    CV 29.01 
 
Tukey's 1 Degree of Freedom Test for Nonadditivity 
Source          DF        SS        MS       F        P
Nonadditivity    1   128.097   128.097    5.33   0.0324 
Remainder       19   456.992    24.052
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Table A.42: Post-Hoc analysis of MA 1 & 2 
 
LSD All-Pairwise Comparisons Test of MA 1 & 2 for TEMPERATURE 
 
TEMPERATURE    Mean  Homogeneous Groups 
      37  23.485  A 
      45  22.143  AB 
      22  17.018   BC 
      60  11.967    C 
 
Alpha              0.05     Standard Error for Comparison  VARIES 
Critical T Value  2.093     Critical Value for Comparison  VARIES 
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APPENDIX B: 
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